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Chapter 1. Introduction-Past, Current Status, and Future Microbial 
Metabolites Research 
Antibiotics, normally including antiviral, monoclonal, antibacterial, antifungal and 
antiparasitic drugs, have been utilized for the last 80 years to treat various infectious diseases, 
such as syphilis, tuberculosis, salmonella, and some forms of meningitis. Until the early 1940s, 
the importance of the antibiotics from microorganisms had been realized, some of them put 
into use in humans. In the long history, microorganisms have made a great contribution to 
people’s health. Concomitantly, widespread use of antibiotics, natural or synthetic, rises 
antibiotics resistance and leads to the emergence of antibiotic resistant bacteria, which reduce 
the efficacy of the drug or even not effective in humans any more. A report of World Health 
Organization states that antibiotic resistance is happening right now in any country and has 
been recognized as a major threat to public health. At this point, new types of antibiotics are 
required to treat infections caused by drug-resistant bacteria or new emerging pathogenic 
bacteria. Recently, marine-derived microorganisms, such as bacteria, fungi and actinomycetes, 
offer a great hope of the drug sighting and development due to the structural diversity and 
unique biological activities of their secondary metabolites, which have not been found among 
those isolated from the terrestrial sources yet. Many of those molecules possess antifungal, 
antibacterial, anti-inflammatory, antitumor, antivirial activities, the activity of kinase inhibitors 
and so on. The application of modern separation, genetic and bioassay screening techniques 
has accelerated novel microbial metabolites discovery.  
1.1 History of Antibiotic Development 
In the history, the development of pharmaceutical industry was oriented by the antibiotics 
produced by terrestrial microorganisms, such as soil-derived fungi and actinomycetes. 
Penicillin antibiotics, among the most well-known antibiotics, were used as the first drugs 
to act effective against many previously serious pathogens caused by staphylococci and 
streptococci. In 1929, bacteriologist Alexander Fleming described the discovery of penicillin 
from Penicillium notatum and its activity against bacteria, and, later in 1940s, penicillin was 
developed into an antibiotic in humans by a group at Oxford (Bugni, T. S., 2004). During the 
World War II, penicillin played an important role in the control of pathogens in the battles and 
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greatly decreased the death of solders. Penicillins are usually very safe and still widely used 
today, though many types of penicillin-resistant bacteria emerged. They are sold in capsule, 
tablet, liquid and injectable forms.  
Streptomycin, the first antibiotic active against tuberculosis, was discovered by Selman 
Abraham Waksman. In 1943, Selman Waksman and his team of students found that 
streptomycin from Streptomyces griseus was active against Mycobacterium tuberculosis. With 
the experimental equipment and financial support from Merck & Company, the results for the 
animals and clinical trials proved that streptomycin was effective chemotherapeutic treatment 
for tuberculosis. 
What is the most significant is that Waksman believed that prices could be reduced if 
several companies could manufacture the drug. Waksman wanted to change the agreement 
giving Merck exclusive rights to the drug. Merck was generous to accept a non-exclusive 
license for the production of streptomycin. 
In addition, including streptomycin and neomycin, Waksman's team discovered more than 
15 antibiotics. Streptomycin and neomycin are extensively applied to treat various infectious 
diseases till now (Ginsberg, J., 2014).  
Fleming and Waksman opened a new age of antibiotics studies and since 1940-1950s 
millions of strains from the soil microbiota have been extensively investigated all over the 
globe and numerous antibiotics have been discovered. Pharmaceutical industries have also 
focused on the soil microbes for more than 50 years (Abad, M. J., 2011).  
Unfortunately, with the development and application of pharmaceutical drugs, 
drug-resistant bacteria have been continuously emerging. An outline of the history of 
antimicrobial agents, and emerging resistant organisms in response to antimicrobial agents are 
shown in Figure 1-1 (Saga, T.; Yamaguchi, K., 2009). Moreover, new antibiotics of the 
marketplace have fallen to less than half the previous level (Coates, A. R.; Hu, Y., 2006). 
However, bacteria, such as MRSA (methicillin-resistant Staphylococcus aureus), 
penicillin-resistant S. pneumoniae and Pseudomonas aeruginosa, have been rising to show 
high levels of resistance among pathogens (Coates, A.; Hu, Y., 2007).  
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Figure 1-1. Trends of antimicrobial agents’ development and drug-resistant bacteria 
emergence 
1.2 Current Status of Microbial Metabolites Research 
The importance of natural products in the discovery of pharmaceutical leads is provided 
by the fact that about half of the best-selling pharmaceuticals in 1991 were either natural 
products or their derivatives and in 1997, 42% were natural products or their derivatives and of 
these, 67% were antibiotics (Demain, A. L., 2009). Nowadays, researchers have been 
continuing searching for new types of metabolites from natural microorganism sources. Till 
2005, among 22 500 biologically active compounds that have been obtained from microbes, 
45% are produced by actinomycetes, 38% by fungi and 17% by unicellular bacteria (Berdy, J., 
2005). Some of these compounds have been developed into antitumor drugs, enzyme inhibitors, 
immunosuppresants, hypocholesterolemic drugs, insecticides, antibacterial agents and so on 
(Demain, A. L., 2009).  
On the other hand, after studied for several decades, metabolites from terrestrial 
microorganism sources appear repetitive. Researchers to some extent have become to preclude 
the study of terrestrial sources and turned to explore unique habitats, such as the marine 
environment (Bugni, T. S., 2004). Ocean covers 71% surface of the earth and inhabits about 
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80% organism resources, which offers unlimited potential for biological and chemical diversity 
(Abad, M. J., 2011). Many natural products researchers continue to focus their effects on the 
studies of marine microorganisms. Novel and bioactive compounds from marine-derived 
microbes were discovered with a 10% increase in the number of compounds reported from the 
previous year, especially a 30% increase from 2010 to 2011 (Blunt, J. W., 2014). At the same 
time, modern genetic methods, high throughput screening techniques (HTS), separation 
technologies and recent advances in microbiological techniques have been developed and 
supported for the compounds discovery from microbes. In 1992, from marine-derived fungi, 
only 15 metabolites were discovered, and, till 2004, more than 272 new compounds were 
isolated (Bhadury, P., 2006). In addition, with the development of modern oceanographic 
science in recent years, humans have expanded to deep-sea regions by means of underwater 
detection and got a chance to collect marine deep-sea microorganisms. Researchers from major 
developed and developing countries are going on by using these advanced tools for drugs 
discovery from the sea. These years, the amount of new compounds discovered from marine 
organisms is rapidly going up and substantial numbers of those are derived from 
microorganisms (Figure 1-2.) (Blunt, J. W., 2013).  
 
Figure 1-2. Variation in number of publications of new marine natural products by 
country over the period 2006–2011. 
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Some marine microbial metabolites possess strong bioactivities and currently are in 
clinical trials (Table 1-1) (Himaya, S. W. A., 2013) (Newman, D. J.; Cragg, G. M., 2014). Some 
of them will be introduced in this paper. 
 
Table 1-1. Marine-derived compounds currently in clinical trials that have evidences of 
microbial origin. 
Clinical status Trade mark Compound Biological activity Microorganism 
Phase III Soblidotin Peptide Anticancer Bacteria 
 
Tectin Tetrodotoxin Antitumor Bacteria 
Phase II Plinabulin Diketopiperazine Anticancer Fungi 
 
Isokahalide  Depsipeptide Anticancer Bacteria 
 
Tasidotin Peptide Anticancer Bacteria 
 
Trabectedin / 
Yondelis 
Alkaloid Anticancer Bacteria 
Phase I Bryostatin 1 Bryostatin 1 Anticancer Bacteria 
  Marizomib 
Beta-lactone- 
gamma-lactam 
Anticancer Bacteria 
Tetrodotoxin, the well-known ‘‘marine toxin’’ acting as a selective blocker of Na+ 
channels, can be found in many marine organisms, such as pufferfish and sea stars. The origin 
of the toxin now has been considered as certain symbiotic marine microorganisms (Chau, R., 
2011). The toxin was first isolated in 1909 by Dr. Yoshizumi Tahara (Clark, R. F., 1999). The 
toxin is now in Phase III trials as an agent (Tectin 
®
) for cancer-related pain in Canada. (WEX 
Pharma INC.)  
Plinabulin
®
, an experimental cancer drug, is in Phase II clinical development under 
Nereus Pharmaceuticals, INC. This agent is a simple modification of a marine fungal 
metabolite halimide (Hayashi, Y., 2013).   
Tasidotin
®
 is an orally active synthetic microtubule-targeted derivative of the marine 
depsipeptide dolastatin-15, is currently undergoing clinical evaluation for cancer treatment 
(Ray, A., 2007).  
Salinosporamide A (Marizomib
®
), the compound discovered from a marine actinomycete, 
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Salinispora tropica, acts as a proteasome inhibitor for disrupting processes related to the 
growth and survival of cancer cells (Potts B.C., et al., 2011). The compound entered Phase I 
clinical trials.  
Trabectedin® or Yondelis®, the first marine-derived anti-neoplastic drug for the 
treatment of advanced soft tissue sarcoma (D’Incalci M., 2014), currently is in Phases I to III. 
This agent was discovered from a mangrove tunicate, Ecteinascidia turbinata. Trabectedin was 
recognized to be produced by symbiotic bacteria (Javed, F., 2011). As only very little amount 
of the compound could be obtained from nature, PharmaMar produced this agent by the 
semi-synthesis from a precursor molecule, cyanosafracin B, from a marine-derived 
microorganism Pseudomonas fluorescens (Cuevas C, 2000).  
    Drugs discovery is still going on. Recently, numerous novel microbial metabolites have 
been continuously discovered. They act various bioactivities and show the potential to turn out 
into pharmaceutical products.  
    An alga-derived fungus Pestalotia sp. produced the potent antimicrobial metabolites, 
pestalone, which showed strong antimicrobial activity against vancomycin-resistant 
Enterococcus faecium (VREF) (MIC = 37 ng/mL) (Cueto, M., 2001). Two new lactones, 
pyrenocines D and E were isolated from the culture of a brown alga derived fungus, 
Penicillium waksmanii. Pyrenocine E showed moderate cytotoxicity against P388 leukemia 
cell line with an ED50 of 1.30 μg/mL (Amagata, T., 1998). Penicillium strain CNC-350 
produced two diketopiperazine dimmers, 11,11’-dideoxyverticillin A and 11’-deoxyverticillin A 
showing potent cytotoxicity against HCT-116 cell line with an IC50 of 30 ng/mL (Son, B. W., 
1999). Pseudoalteromones A and B were obtained from Pseudoalteromonas sp., which was 
cytotoxic to MOLT-4 (human acute lymphoblastic leukaemia) cells (Chen, Y. H., 2012). 
Fradcarbazoles A-C were isolated from Streptomces fradiae from sediment collected from 
Jiaozhou Bay, Shandong, China. These compounds showed significant cytotoxicity against 
HTCLs and acted as the inhibitors of the kinase PKC-α (Fu, P., 2012). JBIR-109 to 111, 
analogues of trichostatin, were isolated from a sponge-derived Streptomyces strain collected 
from Kagoshima, Japan (Hosoya, T., 2012).  
Overall, marine microbes are likely to become a rich source of novel effective drugs due 
to their immense diversity of genetic and biochemical properties. Pharmaceutical industries 
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now accept the ocean as an important aspect of medical research and are concentrating on 
natural products derived from marine microorganisms. PharmaMar (Spain & USA) has put the 
marine drugs research in a leading position (Thakur, N.L., 2005) (Bhatnagar, I.; Kim, S. K., 
2010).  
1.3 Future Trends of Microbial Metabolites Research 
People are exploring the oceans with various high technologies. China, Japan, the United 
States, France and Russia have developed deep-water technology. For example, manned 
research submersibles JiaoLong (China) and Sinkai 6500 (JAMSTEC , Japan) can now dive to 
a depth of over 7 000 m and 6 500 m, which can be used to collect microorganisms from 
deep-sea. Very recently, several research groups have begun to seek novel microbial 
metabolites derived from deep-sea and rapidly there are some reports about their works. The 
deep-sea-derived Streptomyces sp. SCSIO 03032 was capable of producing new bisindole 
alkaloids, spiroindimicins A–D, which exhibited moderate cytotoxicities against several cancer 
cell lines (Zhang W., 2012). New spirotetronate antibiotics, Lobophorins H and I, were isolated 
from a South China Sea-Derived Streptomyces sp. 12A35 from the sediment collected at the 
depth of about 2000 metres. Lobophorin H showed a strong activity against Bacillus subtilis 
CMCC63501 with the MIC value of 3.13 μg/mL, while Lobophorin I possessed moderate 
activity with the MIC value of 6.25 μg/mL (Pan, H. Q., 2013). Besides the pharmaceutical 
leads, deep-sea derived microorganisms also offer other useful agents, like antifouling 
compounds. Some antifouling potentials of deep-sea-derived fungi from the South China Sea 
have been reported (Zhang, X. Y., 2014). Besides, new laboratory of deep-sea derived 
microorganisms has been set up very recently. Dr. McPhail’s research team of Oregon State 
University, USA started a program of elicitation of antibiotic natural products in multispecies 
cultures of deep-sea vent-derived microorganisms. The studies of deep-sea microorganisms 
have just started and the deep-sea microorganisms are potential to be a rich source for drugs 
discovery. 
New culture techniques, such as fungal fermentation studies by adding histone 
deacetylases (HDAC) and histone acetyl transferases (HAT) inhibitors have been applied to 
metabolites discovery as reported by Oshima’s team, 2013. They found six new 
benzophenones cephalanones A–F from an endophytic fungus, Graphiopsis Chlorocephala, 
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only produced in the presence of an NAD
+
-dependent HDAC inhibitor (Asai, T., 2013). 
Though the technique was applied to the terrestrial fungus, in the near future there could be 
several reports of marine-derived fungi. 
The news reported in Oct. 2014 by Meera Senthilingam, for CNN had the headline “We're 
growing bacteria in space, and they could help us create new vaccines”. There is always a hope 
that space-derived new drugs can treat the refractoriness we are facing now, which the 
traditional types cannot do. 
Overall, people are continuing inventing new technologies to yield microbial metabolites 
with unique biochemical and structural diversity or to find novel targets for vaccines and 
therapies, which offer a great hope of the human survival and the civilization development. 
1.4 Objective of This Research 
    As discussed above, marine-derived microbial metabolites continue to be a potential 
source of new drugs discovery. The purpose of this research is to discover new compounds 
from marine-derived actinomycetes and fungi. Bioassay methods, including antibacterial, 
antifungal and anti-mycobacterial tests were used for the screening of culture broth of 
microbial strains. Bioassay-guided isolation from two fungi and one actinomycete strains 
extracts yielded 8 new compounds, and their bioassay activities are discussed.  
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Figure 1-3. Structures of selected marine-derived microbial agents currently in clinical 
trials 
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Figure 1-4. Structures of selected marine-derived microbial metabolites. 
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Figure 1-5. Structures of selected marine-derived microbial metabolites obtained by the 
application of new techniques. 
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Figure 1-5. Continued. 
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2. Isolation and Characterization of New Anti-Mycobacterial Nucleoside 
Antibiotics from a Marine-Derived Streptomyces sp. TPU1236A 
2.1 Introduction 
Tuberculosis (TB) is a high incidence of contagious disease in humans caused by various 
strains of mycobacteria, usually Mycobacterium tuberculosis (Kumar, V., 2007), which 
typically attacks the lungs (Konstantinos, A., 2010).
 
It’s assumed that one-third of the world’s 
population have been infected with the M. tuberculosis complex, although not yet ill with 
active TB (WHO, 2010).
 
The World Health Organization (WHO) estimates that active cases of 
tuberculosis afflict nearly 9 million people annually, and lead up to 1.4 million deaths per year 
(WHO, 2013).
 
Tuberculosis chemotherapy involves a combination bacteriostatic antibiotics of 
isoniazid (INH) and rifampin (RFP) for at least 6 months, and pyrazinamide (PRZ) and 
ethambutol (EMB) or streptomycin (SPM) for the first 2 months of treatment (Askgaard, D.S., 
1995).
 
However, drugs for treating tuberculosis are far from ideal. Severe side effects 
associated with anti-TB drugs are common among patients hospitalized for pulmonary 
tuberculosis as reported (Gülbay, B. E., 2006).
 
Besides, M. tuberculosis always acquires drug 
resistance mainly due to its lipid-rich cell wall acting as a permeability barrier from drugs
 
and 
inadequate chemotherapy (Louw, G. E., 2009) (Michael, D., 1993),
 
which mainly caused 
multi-drug-resistant tuberculosis
 
(Dalton, T., 2012) (MDR-TB: resistance to at least isoniazid 
and rifampicin) and extensively-drug resistant TB
 
(WHO, 2006) (M/XDR-TB: MDR resistance 
plus resistance to a fluoroquinolone and an amionoglycoside). The multi-drug-resistant type of 
tuberculosis further complicated the problem of TB control (Michael, D., 1993).
 
More recently, 
the totally drug resistant TB (TDR-TB), which is resistant to all second-line drugs, have often 
been reported from India and the other Asian countries. Although a new drug, delmanid 
(Deltyba®), which inhibits the cell wall biosynthesis of mycobacteria, has been approved in 
2014 for the treatment of MDR-TB in EU and Japan (Ryan, N.J., 2014) (Xavier, A.S., 2014), 
continuous efforts to discover new anti-TB agents with novel mechanisms of action and 
structural features are the emergent global demand. During our continuous research for anti-TB 
drugs produced by marine organisms, marine actinomycetes, as a new resource for natural 
products discovery, currently received considerable attention (Fenical, W., 2006).
 
Increasing 
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evidences reveal that marine actinomycetes offer a great hope of the drug sighting and 
development due to the structural diversity and unique biological activities of their secondary 
metabolites, which have not been found among those isolated from the terrestrial sources yet 
(Zotchev, S. B., 2012). 
As a part of our search for anti-TB compounds produced by marine actinomycetes 
collected from Iriomote Island, Okinawa, Japan, we evaluated the anti-mycobacterial activity 
against Mycobacterium smegmatis NBRC 3207 of EtOAc extracts of bacterial culture broth by 
the paper disc method. M. smegmatis has been the most widely studied due to its fast growing 
and non-pathogenicity compared to other mycobacterial pecies (Reyrat, J .M., 2001).
 
The 
EtOAc extract of culture broth of a marine-derived Streptomyces sp. (strain TPU1236A) was 
found to exhibit the strongest antibacterial activity against M. smegmatis NBRC 3207. 
Activity-guided purification of the culture broth yielded five compounds, designated 
streptcytosines A—E (1—5) (Bu, Y. Y., 2014), along with six known compounds: 
de-amosaminyl-cytosamine
 
(6), plicacetin (7), bamicetin (8), amicetin (9), collismycin A (10) 
and SF2738C (11)
 
(Chen, R., 2013)
 
(Haskell, T. H., 1958) (Hinman, J.W., 1953) (Gomi, S., 
1994) (Figure 2-1 & 2-2). 
 
Figure 2-1. Structures of compounds 1—5. 
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Figure 2-2. Structures of compounds 6—11. 
 
2.2 Results and Discussion 
The strain TPU1236A was isolated from a seawater sample collected at Iriomote Island in 
Okinawa, Japan. The gene sequence used for the identification showed 100% identity with those 
of Straptomyces badius and Streptomyces sindenensis. The bacterium was cultured by shaking in 
a liquid medium for 7 days at 25 °C in the dark. The extracts of broth filtrates and mycelia were 
subjected to ODS silica gel column chromatography followed by preparative HPLC separation 
as described in the Experimental Section to afford compounds 1–11. Six known compounds 
were identified the structures by comparing the spectroscopic data for 6–11 with those of the 
reported values for de-amosaminyl-cytosamine (6), plicacetin (7), bamicetin (8), amicetin (9), 
collismycin A (10), and SF2738 C (11), respectively. 
 
2.2.1 Screening Bioassay 
Anti-mycobacterial screening was carried out using M. smegmatis NBRC 3207 by the 
paper disc method.
 
Test microorganism was inoculated to a petri dish containing the 7H9 agar. 
A sterile antibiotic filter disc (diameter, 6 mm, Advantec, Tokyo, Japan) with the sample was 
placed in the dish and cultured for 2 days at 37 °C. The inhibition zone in diameter (mm) was 
measured and above 8 mm in diameter of the inhibition zone was considered as a positive 
result. The crude extract of the bacterium strain TPU1236A showed the strongest inhibitory 
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activity against M. smegmatis NBRC 3207 among 40 extracts of marine–derived 
microorganisms collected at Iriomote Island. (Figure 2-3) 
 
 
Figure 2-3.  Sampling sites of marine-derived actinomycetes (2012) 
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Table 2-1.  Anti-mycobacterial screening (inhibition zone: nm) against Mycobacterium 
smegmatis NBRC 3207. 
Strain 
EtOAc extract of broth 
(50 μg/disc)  
Strain 
EtOAc extract of broth 
(50 μg/disc)  
TPU1201A —a TPU1221A — 
TPU1202A — TPU1222A — 
TPU1203A — TPU1223A — 
TPU1204A — TPU1224A 9 
TPU1205A — TPU1225A 29 
TPU1206A — TPU1226A — 
TPU1207A — TPU1227A — 
TPU1208A — TPU1228A — 
TPU1209A — TPU1229A — 
TPU1210A — TPU1230A — 
TPU1211A — TPU1231A — 
TPU1212A — TPU1232A — 
TPU1213A — TPU1233A 19 
TPU1214A   9 TPU1234A 14 
TPU1215A  17 TPU1235A — 
TPU1216A — TPU1236A 35 
TPU1217A   8 TPU1237A 35 
TPU1218A — TPU1238A — 
TPU1219A   9 TPU1239A — 
TPU1220A — TPU1240A — 
streptomycin 
sulfate 
b
  
30 methanol 
c
 — 
a
: An inhibition zone was not detected.     
b
: Positive control (5 μg/disc).          
c
: Negative control (10 μL/disc). 
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2.2.2 Isolation of Compounds 
The producing actinomycete, Streptomyces sp. (strain TPU1236A) was isolated from a 
seawater sample collected at Iriomote Island, Okinawa Prefecture, Japan. The bacterium was 
cultured on a liquid medium by shaking for 7 days at 25 °C in the dark. After cultivation, the 
colonies were harvested and extracted with methanol. The extracts were separated by 
combination of chromatographic procedures to afford streptcytosines A—E (1—5), 
de-amosaminyl-cytosamine (6), plicacetin (7), bamicetin (8), amicetin (9), collismycin A (10) 
and SF2738C (11). (Figure 2-4) 
 
  
Streptomyces sp. 
TPU1236A      
 
   
seed culture (30 mL, 27 ℃, 150 r.p.m, 3 days)  
 
 
   
main culture (10.0 L, 27 ℃, 150 r.p.m, 21 days)   
 
 
  
broth 
     
 
   
filtered 
     
 
 
        
    
 filtrate 
  
mycelial cake 
   
 
 
open column-HP20 
  
extracted with MeOH 
 
 
 
washed with H2O  
 
MeOH extract  
   
 
 
eluted with MeOH   
    
 MeOH eluent 
 
  
    
 
 
evaporated MeOH   
    
 
  
 
extract (1.5 g)      
 
   
open column-ODS 
    
 
 
              
 
 Fr.8 
   
Fr.9 Fr.10 
 
 
HPLC-ODS 
   
HPLC-ODS HPLC-ODS 
 
 
60% MeOH, 0.05% 
TFA   
45% MeOH,  
0.05% TFA  
36% MeOH,  
0.05% TFA 
                       
 
Figure 2-4. Bioassay-guided isolation procedure for the whole broth extract. 
2     3    4      5     6     8     1      7    10     11        9 
(3.2mg) (7.2mg)(8.1mg)(5.1mg)(12.0mg)(20.5mg)(12.3mg)(21.3mg)( 11.2mg)( 6.8 mg) (25.0mg) 
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2.2.3 Structure Determination of New Compounds  
Streptcytosine A (1) was obtained as colorless oils. The molecular formula of C30H42N6O9 
was deduced from HRFABMS ([M+H]
+
 peak at m/z 631.3110, calcd for C30H43N6O9, Δ +1.9 
mmu), 
1
H and 
13
C NMR spectral data analysis (Table 2-2). The 
1
H NMR spectrum (in CD3OD) 
displayed 37 proton signals. The other five active protons present in 1 were suggested by 
comparing with the amount of hydrogens in the molecular formula. The connectivity of proton 
and carbon atoms was established by the HMQC spectrum (Table 2-2). The presence of 30 
carbons including five methyl, two sp
3
 methylene, one oxygenated sp
3 
methylene, one 
nitrogenated sp
3 
methylene, five oxygenated sp
3 
methine, one nitrogenated sp
3
 methine, two 
anomeric sp
3
 methine, five sp
2
 methine, one nitrogenated sp
2
 methine, one sp
2
 quaternary, one 
nitrogenated sp
3
 quaternary, one nitrogenated sp
2
 quaternary, and three amide carbonyl carbons 
was decided by the analysis of the 
13
C NMR, DEPT and HMQC spectra.  
Detailed 2D analysis revealed that 1 was composed of the C-2, C-4 to C-6 giving a 
cytosine (Zhang, G., 2012), the carbons from C-1’ to C-6’ and C-1’’ to C-6’’ containing a 
disaccharide, C-8 to C-14 forming a p-aminobenzoic acid (PABA) and 4-imidazolidinone by 
C-16, C-17, C-19, C-20 and C-21 (Figure 2-5).
 1
H-
1
H COSY analysis gave the partial 
structures I to IV (Figure 2-5). The presence of a nucleotide cytosine in 1 was confirmed by the 
partial structure II and HMBC correlations (Figure 2-5) from H-6 to C-2 and from H-6 to C-4.
 
A disaccharide unit in 1 was determined by two connected sugars. The partial structure III was 
cyclized to form a sugar called 3-hydroxyamicetose, which was deduced from the HMBC 
correlations (Figure 2-5) from H-1’ to C-5’ forming an oxygenated bond. Another oxygenated 
bond from H-1’’ to C-5’’ was also observed by the HMBC correlation (Figure 2-5) and, 
together with the partial structure IV, a pyranose ring structure was proved. Besides, two 
coupled nitrogenated sp
3
 methyls H-7’’ and 8’’ were observed and attached with C-4’’, which 
was suggested by the HMBC correlations (Figure 2-5) from H-7’’ and H-8’’to C-4’’ to give the 
amino sugar called amosamine. 3-Hydroxyamicetose connected with amosamine by an 
α-(1→4)-glycoside bond, which was suggested by an HMBC correlation (Figure 2-5) form 
H-1’’ to C-4’. Cytosine and 3-hydroxyamicetose moieties were connected together by an 
observed HMBC correlation (Figure 2-5) from H-6 to the anomeric C-1’. As plicacetin (7), the 
presence of PABA unit was deduced from two aromatic carbon signals at δ 130.8 and δ 120.6 
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(partial structure I) and an HMBC correlation (Figure 2-5) from H-14 to an amide carbonyl 
carbon at C-8, together with one nitrogenated sp
2
 methine at C-12 and one sp
2
 quaternary 
carbon at δC 131.6. Unlikely bamicetin (8) and amicetin (9) containing an α-methyl-serine, a 
4-imidazolidinone was present in 1, which was deduced from the HMBC correlations (Figure 
2-5) from H-21 to C-16 and C-17, from H-19 to C-16 and C-17 and from H-20 to C-16 , C-17 
and C-19 (Figure 2-5). These data gave the planer structure of 1 as shown in Figure 2-5.  
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Table 2-2. 
13
C (100 MHz) and 
1
H (400 MHz) NMR data for streptcytosine A (1) (CD3OD). 
C#   δC     δH, mult. (J in Hz) HMBC 
2 157.4   
4 165.0   
5 99.1 7.58, d, (7.5) 6  
6 146.7 8.21, d, (7.6) 2, 4, 5, 1’ 
8 168.4   
9 131.6   
10 130.8 8.10, d, (8.8) 8, 11, 12, 14 
11 120.6 7.87, d, (8.9) 10, 13 
12 142.0   
13 120.6 7.87, d, (8.8) 11, 14 
14 130.8 8.10, d, (8.9) 8, 10, 12, 13 
16 172.2   
17 68.3   
19 66.1 (a) 3.83, d, (11.6) 16, 17 
  (b) 4.03. d, (11.6) 16 
20 17.6 1.57, s 16, 17, 19 
21 61.1 5.28, br s 16, 17 
1’ 84.9 5.79, d, (7.8)  
2’ 31.1 (a) 2.19, br d, (9.1) 4’ 
  (b) 1.71, m 4’ 
3’ 28.1 (a) 1.71, m 1’ 
  (b) 2.41, m  
4’ 76.7 3.46, m  
5’ 78.4 3.77, dq, (9.0, 6.1) 4’ 
6’ 19.3 1.39, d, (6.0) 4’, 5’ 
1” 96.8 5.03, d, (3.7) 4’, 3”, 5” 
2” 74.0 3.56, dd, (9.2, 3.6) 3” 
3” 68.1 3.98, dd, (11.9, 9.0) 2”, 4” 
4” 72.1 3.12, dd (10.2, 10.2) 3”, 5”, 6”, 7”, 8” 
5” 64.2 4.10, dq, (9.8, 6.3)  
6” 19.1 1.47, d, (6.1) 4”, 5” 
7” 42.6 3.01, s 4”, 8” 
8” 42.6 3.01, s 4”, 7” 
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Figure 2-5. 
1
H-
1
H COSY and HMBC data for compound 1 
Since streptcytosine A (1) was obtained together with plicacetin (7), bamicetin (8), and 
amicetin (9) from the strain TPU1236A, the absolute configuration of the sugar moiety will be 
the same, which was also confirmed by J values. The configuration of 1 at the C-17 position was 
also assigned to be the same as those of 8 and 9, since these compounds should be biosynthesized 
by the same pathway. Moreover, compounds 1 (+72), 7 (+96), 8 (+66), and 9 (+76) showed the 
same positive specific rotation. Therefore, streptcytosine A (1) may share the same configuration 
for whole asymmetric carbons as compounds 8 and 9, as depicted in Figures 2-1 and 2-2. 
Therefore, streptcytosine A (1) may share the same configuration for whole asymmetric carbons 
as compounds 8 and 9, as depicted in Figure 2-1 and 2-2. 
Streptcytosine B (2) was isolated as pale yellow oils. The molecular formula of 2, 
C14H19N3O4S, was established by HRFABMS ([M+H]
+
 peak at m/z 326.1180, calcd for C14H20 
N3O4S, Δ +0.6 mmu), 
1
H and 
13
C NMR spectral data analysis (Table 2-3). The 
13
C NMR 
spectrum (in CD3OD) showed the signals for two methyl, two sp
3
 methylene, two oxygenated 
sp
3 
methine, one anomeric sp
3
 methine, two sp
2
 methine, one nitrogenated sp
2
 methine, one 
sulfureted sp
2
 methine, one nitrogenated sp
2
 quaternary, and two amide carbonyl carbons by 
the analysis of the DEPT and HMQC spectra.  
1
H and 
13
C data for 2 suggested the presence of 3-hydroxyamicetose and cytosine moieties 
in 2, the same as those in 1 by comparing their NMR spectra data (Table 2-2 and 2-3). Besides, 
the 
1
H-
1
H COSY analysis of 2 revealed the presence of the partial structure V (Figure 2-6) and 
attached with the carbonyl carbon at C-8 by the analysis of HMBC correlations from H-9 to 
C-8 and from H-10 to C-8. One sulfureted sp
3
 methyl signal at δ 2.44 (H-11) was assumed to 
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bond to the partial structure V by HMBC correlations (Figure 2-6) from H-11 to C-10. The 
trans-configuration of the olefin bond at C-9 in partial structure V was determined by the 
coupling constant (14.5 Hz). Thus, the planer structure of 2 was determined. The relative 
configuration of 3-hydroxyamicetose moiety in 2 was considered as the same as 1 due to their 
similiar 
1
H and 
13
C NMR signals (Table 2-2 and 2-3). Thus, the structure of 2 was determined. 
Streptcytosine C (3) had the molecular formula of C15H21N3O4 as established from 
HRFABMS ([M+H]
+
 peak at m/z 308.1619, calcd for C15H22N3O4, Δ +0.9 mmu), and 
1
H and 
13
C NMR spectral data analysis (Table 2-3). 
1
H NMR and 
13
C NMR data (Table 2-3) for 3 were 
similar to those for 2, except the presence of the partial structure VI (Figure 2-6) in the 
carboxylic acid moiety, showing the structure of 2-methyl-2-butenoic acid, which was deduced 
from 
1
H-
1
H COSY and HMBC correlations (Figure 2-6) from H-12 to C-8 , H-10 to C-8, H-10 
to C-12 and from H-11 to C-9. In VI, an NOE correlation was observed only between H-10 and 
H-11 but not between H-10 and H-12. 
1
H and 
13
C NMR data due to the 2-methyl-butenoic acid 
moiety’s in 3 were very similar to those of cytosaminomycin D (Shiomi, K., 1994), which 
indicated the trans-configuration for the double bond at C-9 (Figure 2-6). The configuration of 
the 3-hydroxyamicetose moiety in 3 was considered to be the same as 2 due to their similar 
1
H 
and 
13
C NMR signals (Table 2-3). 
Streptcytosine D (4) was assigned to the same molecular formula as 3, C15H21N3O4, by 
HRFABMS ([M+H]
+
 peak at m/z 308.1601, calcd for C15H22N3O4, Δ-1.0 mmu), 
1
H and 
13
C 
NMR spectral data (Table 2-3). 
1
H and 
13
C NMR data (Table 2-3) for 4 and 3 were almost 
identical, except that a 3-methylcrotonic acid moiety existed in VII, which was identified by 
1
H-
1
H COSY and HMBC correlations (Figure 2-6) from H-12 to C-10 and C-11 and from H-9 
to C-8, C-10 and C-11 (Figure 2-6). The configuration of 3-hydroxyamicetose moiety in 4 was 
considered to be the same as 3 due to their similar 
1
H and 
13
C NMR signals (Table 2-3). 
Streptcytosine E (5) had the molecular formula of C15H23N3O4 determined from 
HRFABMS ([M+H]
+
 peak at m/z 310.1763, calcd for C15H24N3O4, Δ -0.4 mmu), 
1
H and 
13
C 
NMR data (Table 2-3). 
1
H and 
13
C NMR data (Table 2-3) for 5 were highly similar to those for 
4. The partial structure VIII, a propanoic acid moiety existing in carboxylic acid moiety was 
deduced to be different from 4 by 
1
H-
1
H COSY and HMBC correlations. The planar structure 
of 5 was confirmed by detailed 2D NMR data analysis (Figure 2-6). 
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             Table 2-3. 
13
C (100 MHz) and 
1
H (400 MHz) NMR data for streptcytosines B—E (2–5) (CD3OD). 
 2  3  4  5 
C# δC 
δH, mult. 
(J in Hz) 
 δC 
δH, mult. 
(J in Hz) 
 δC 
δH, mult. 
(J in Hz) 
 δC 
δH, mult. 
(J in Hz) 
2 
4 
5 
 
6 
 
8 
9 
 
10 
 
11 
 
12 
 
1’ 
 
2’ 
 
3’ 
 
4’ 
5’ 
 
6’ 
156.6 
164.6 
98.4 
 
146.8 
 
166.2 
115.7 
 
150.7 
 
14.7 
 
–– 
 
85.0 
 
32.4 
 
31.7 
 
71.8 
80.7 
 
18.6 
 
 
7.34, d 
(7.5) 
8.19, d 
(7.5) 
 
6.07, d 
(14.6) 
8.01, d 
(14.6) 
2.42, s 
 
–– 
 
5.71, dd 
(9.9, 2.1) 
(a) 2.15, m 
(b) 1.67, m 
(a) 1.67, m 
(b) 2.13, m 
3.28, m 
3.51, dq 
(9.1, 6.1) 
1.34, d 
(6.1) 
 155.5 
164.2 
98.3 
 
147.5 
 
171.3 
133.5 
 
137.4 
 
14.7 
 
12.2 
 
85.0 
 
32.4 
 
31.7 
 
71.7 
80.7 
 
18.6 
 
 
7.30, d 
(7.6) 
8.23, d 
(7.6) 
 
 
 
6.71, q 
(7.0) 
1.89, d 
(7.0) 
1.90, s 
 
5.71, dd 
(10.1, 2.2) 
(a) 2.16, m 
(b) 1.67, m 
(a) 1.67, m 
(b) 2.13, m 
3.28, m 
3.51, dq 
(9.2, 6.2) 
1.34, d 
(6.2) 
 154.2 
164.3 
98.2 
 
147.0 
 
168.2 
118.7 
 
161.3 
 
28.0 
 
20.8 
 
84.9 
 
32.4 
 
31.6 
 
71.8 
80.6 
 
18.6 
 
 
7.26, d 
(7.5) 
8.21, d 
(7.5) 
 
5.95, qq 
(1.3, 1.3) 
 
 
1.99, d 
(1.2) 
2.24, d 
(1.2) 
5.71, dd 
(10.0, 2.2) 
(a) 2.15, m 
(b) 1.67, m 
(a) 1.67, m 
(b) 2.12, m 
3.27, m 
3.51, dq 
(9.1. 6.1) 
1.33, d 
(6.1) 
 157.8 
164.8 
99.2 
 
146.7 
 
176.5 
47.3 
 
27.1 
 
22.7 
 
22.7 
 
84.9 
 
32.4 
 
31.7 
 
71.8 
80.6 
 
18.6 
 
 
7.47, br d 
(7.6) 
8.12, d 
(7.6) 
 
2.32, d 
(7.2) 
2.10, m 
 
0.99, d 
(6.7) 
0.99, d 
(6.7) 
5.70, dd 
(9.9, 1.8) 
(a) 2.15, m 
(b) 1.66, m 
(a) 1.66, m 
(b) 2.12, m 
3.28, m 
3.50, dq 
(9.2, 6.2) 
1.33, d 
(6.2) 
25 
 
Figure 2-6. 
1
H-
1
H COSY and HMBC data for compounds 2—5 
 
2.2.4 Structure Determination of Known Compounds 
Compound 6 was obtained as obtained as a colorless oil. The molecular weight and 
molecular formula, 225 and C10H15N3O3, were decided by the analysis of 
1
H and 
13
C NMR 
spectra and FABMS data. Compound 6
 
had very similar 
1
H NMR (CD3OD, 400 MHz) 
spectrum as those of compounds 2-5. In the 13C NMR (CD3OD, 100 MHz) spectrum of 
compound 6, similar chemical shifts at δ 161.9, 148.9, 146.4 and 95.3 of a cytosine moiety 
were observed. The planer structure of compound 6 was determined by HMBC, HMQC and 
1
H-
1
H COSY correlations. The absolute configuration of compound 6 was considered to be the 
same as the known compound de-amosaminyl-cytosamine by comparing the chemical shifts 
with those of reported values (Chen, R., 2013). Therefore, the structure of compound 6 was 
determined. 
Compound 7 was obtained as a yellow oil. The molecular weight and molecular formula, 
517 and C25H35N5O7, were decided by the analysis of 1H and 13C NMR spectra and FABMS 
data. The 
1
H and 
13
C NMR spectra of compound 7 showed similar signals to those of 
compound 1. The planer structure of compound 7 was determined by HMBC, HMQC and 
1
H-
1
H COSY correlations. Compound 7 had a positive specific rotation of +96 (c 0.1, MeOH) 
which was very close to the reported value of plicacetin. (Haskell, T. H., 1958) The 
1
H and 
13
C 
chemical shifts in CD3OD of plicacetin were also reported by Chen, R., 2013. Thus, compound 
26 
7 was considered as a known compound plicacetin. 
Compound 8 was obtained as a pale yellow oil. The molecular weight and molecular 
formula, 604 and C28H40N6O9, were decided by the analysis of 
1
H and 
13
C NMR spectra and 
FABMS data, which were the same as a Streptomyces derived antibiotic, bamicetin. The planer 
structure of compound 8 was determined by HMBC, HMQC and 
1
H-
1
H COSY correlations. 
Compound 8 showed a positive specific rotation of +66 (c 0.1, MeOH) and was confirmed as a 
known antibiotic bamicetin.  
Compound 9 was obtained as a pale yellow oil. The molecular weight and molecular 
formula, 618 and C29H42N6O9, were decided by the analysis of 
1
H and 
13
C NMR spectra and 
FABMS data. These data were identical with those of an anti-mycobacterial antibiotic, 
amicetin, which was isolated from Streptomyces sp. together with bamicetin (8) and plicacetin 
(7). The planer structure of compound 9 was determined by HMBC, HMQC and 
1
H-
1
H COSY 
correlations. Compound 9 had a positive specific rotation of +76 (c 0.1, MeOH) and was 
identified as amicetin. 
Compound 10 was obtained as a colorless crystal. The molecular weight and molecular 
formula, 275 and C13H14N3O2S, were decided by the analysis of 
1
H and 
13
C NMR spectra and 
FABMS data. The structure of compound 10 was established by HMBC, HMQC and 
1
H-
1
H 
COSY correlations. The 
1
H NMR showed similar signals to that of collismycin A and the 
structure of compound 10 was confirmed. 
Compound 11 was obtained as a pale yellow oil. The molecular weight and molecular 
formula, 262 and C13H15N2O2S, were decided by the analysis of 
1
H and 
13
C NMR spectra and 
FABMS data. The 
1
H and 
13
C NMR chemical shifts of compound 11 were similar to those of 
compound 10. The structure of compound 10 was determined by HMBC, HMQC and 
1
H-
1
H 
COSY correlations and was confirmed as
 
SF2738C. 
2.2.5 Biological Activity of Isolated Compounds 
The antibacterial activities of compounds 1—11 against M. smegmatis NBRC 3207 were 
evaluated using the paper disc method (Ericsson, H., 1960), and MICs were determined by the 
liquid microdilution method using 96-well plastic plates (Table 2-4). 
Compounds 1, 7–9, and 11 showed activity against M. smegmatis at 5 g/disc. Amicetin (9) 
was reported to inhibit the growth of M. tuberculosis (Amsterdam, D., 1996) and showed 
strong activity against M. smegmatis in our experiment. The inhibition activity of compounds 1 
27 
and 7 (MIC = 32 g/mL) was about a half of that of compounds 8 (MIC = 16 g/mL). 
Therefore, the 2-methylserine moiety attached to the PABA unit will be important for the 
anti-mycobacterial activities of these compounds. 
On the other hand, compounds 2–6 were not active against M. smegmatis at 50 g/disc. 
Consequently, the amino sugar (amosamine) will be essential for anti-mycobacterial activity. 
Table 2-4. Anti-mycobacterial activities (inhibition zone: mm) of compounds 1–11 against 
Mycobacterium smegmatis NBRC 3207. 
Compound 5 g/disc 10 g/disc MIC (g/mL) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
streptomycin sulfate 
9 
––a 
–– 
–– 
–– 
–– 
9 
18 
21 
–– 
9 
30 
12 
–– 
–– 
–– 
–– 
–– 
13 
24 
26 
12 
12 
38 
   32 
n.d.
b
 
n.d. 
n.d. 
n.d. 
n.d. 
 32 
 16 
  8 
>64 
  64 
      0.50 
a
: An inhibition zone was not detected. 
b
: Not determined. 
 
  
2.3 Experimental Section 
2.3.1 Gernal Experimental Procedures 
Optical rotations were measured with a JASCO P-2300 digital polarimeter (JASCO, Ltd., 
Japan). UV spectra were obtained on a Hitachi U-3310 UV-Visible spectrophotometer (Hitachi, 
Ltd., Japan) and IR spectra on a PerkinElmer Spectrum One Fourier transform infrared 
spectrometer (Waltham, MA, USA). NMR spectral data were obtained by a JEOL 
JNM-AL-400 NMR spectrometer (JEOL Ltd., Japan; 400 MHz for 
1
H and 100 MHz for 
13
C) in 
CDCl3 (δH 7.24, δC 77.23), CD3OD (δH 3.31, δC 49.0) or DMSO-d6 (δH 2.50, δC 39.51). 
28 
High-resolution FAB mass spectra were recorded on a JEOL JMS-MS 700 mass spectrometer 
(JEOL Ltd., Japan). Preparative HPLC was conducted using a Toyosoda CCPU instrument 
with a Tosoh UV-8010 detector. 
2.3.2 Isolation, Identification and Fermentation of Producing Bacterium 
Streptomyces sp. strain TPU1236A was isolated from a seawater sample collected at 
Iriomote Island, Okinawa Prefecture, Japan in September, 2012. Approximately 1 mL of the 
seawater was mixed with 25 mL of sterilized seawater with 1.0 % SDS, and 50 μL of the 
mixture was developed on an agar plate, containing glycerol 0.6%, arginine 0.1%, K2HPO4 
0.1%, MgSO4 0.05%, agar 1.5% and antibiotics (cycloheximide 100 μg/mL and rifampin 5 
μg/mL) in natural seawater according to the method described by Fenical et al (Mincer, T. J., 
2002).
 
Identification of the strain TPU1236A was carried out by comparing partial seaquence 
of the 16S rRNA gene. S. badius (732/732, 100%) and S. sindenensis (730/730, 100%) showed 
the highest similarity. Therefore, this producing strain TPU1236A was identified as 
Streptomyces sp. (Figure 2-7) 
 
 
Figure 2-7. Picture of marine-derived actinomycete Streptomyces sp. TPU1236A grown on 
an agar plate. 
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The culture of strain TPU1236A was maintained on a Waksman agar slant (glucose 1%, 
peptone 0.5%, meat extract 0.5%, NaCl 0.3%, and agar 1.2% in deionized water) at 4 °C. The 
mycelia grown on the slant culture was inoculated in a 100-mL Erlenmeyer flask containing 40 
mL of a seed medium (ASW-A medium: soluble starch 2%, glucose 1%, peptone 0.5%, yeast 
extract 0.5%, and CaCO3 0.3% in natural seawater, pH 7.0), and the flasks were shaken (150 
rpm) at 25 °C for 3 days. The seed culture (2 mL) was transferred into 500-mL Erlenmeyer 
flasks containing each 200 mL of the same medium and incubated at 25 °C for 7 days at 150 
rpm. 
2.3.3 Bioassay 
Anti-mycobacterial assay was carried out using M. smegmatis NBRC 3207 by the paper 
disc method and liquid microdilution method.
 
The strain M. smegmatis NBRC 3207 was 
obtained from the Biological Resource Center (NBRC), NITE (Chiba, Japan) and maintained 
in 20% glycerol at –80 °C. 
The test microorganism was cultured in Middlebook 7H9 broth (BD, Franklin Lakes, NJ) 
containing 0.05% polysorbate 80 (BD), 0.5% glycerol, and 10% Middlebook OADC (BD) at 
37 ˚C for 2 days and adjusted to 1.0 × 106 CFU/mL. After incubation for 2 days at 37 °C, a 
petri dish was inoculated with the culture broth containing the bacterium. Then a sterile 
antibiotic filter disc (diameter, 6 mm, Advantec, Tokyo, Japan), treated with the sample 
solution in MeOH (2 μL), was placed in the dish. After evaporation of MeOH, the disc was 
placed in a plate and incubated for 2 days at 37 ˚C. The inhibition zone in diameter (mm) was 
measured. Streptomycin sulphate (5 and 10 μg) and MeOH were used as positive and negative 
controls, respectively. 
MICs were measured by the liquid microdilution method (Koyama, N., 2010). After 85 μL 
of Middlebrook 7H9 broth containing 0.05% polysorbate 80, 0.5% glycerol, and 10% 
Middlebook OADC was added to each well of a 96-well microplate (Corning Inc., Corning, 
NY, USA), test compound dissolved in MeOH (5.0 μL) was added to each well at the final 
concentration of 0.125 to 64 μg/mL. Finally, the test microorganism (10 μL) was added at a 
concentration of 1.0 × 106 CFU/mL. Microplates were incubated at 37 ˚C for 2 days. MIC 
was defined as the lowest concentration of test compound where the test microorganism did not 
grow. 
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2.3.4 Extraction and Isolation of Streptcytosines 
The whole broth (10.0 L) was filtered and the mycelia were extracted with 1 L methanol 
and filtered. The broth filtrate was absorbed on a Diaion HP-20 column (500 mL), and the 
column was washed with water (2 L) and eluted with methanol (2 L). After evaporation of 
methanol in vacuum, the extracts from water phase and mycelia were combined to give about 
1.5 g of solid material. The residue was fractioned by ODS column chromatography by 
stepwise elution with MeOH-H2O to obtain 11 fractions. Streptcytosine A (1), eluted in the 
70% MeOH fraction was purified by preparative reversed-phase HPLC (Senshu Scientific co., 
Ltd., PEGASIL ODS SP100 column, 250 mm × 10 mm, 5 μm; MeOH-H2O, 6: 4, 0.05% TFA; 
2.0 mL/min; UV 210 nm). Streptcytosine A (1, 12.3 mg), plicacetin (7, 21.3 mg), SF2738C (11, 
6.8 mg) eluted at 9.9, 15.0 and 12.2 min, respectively. Collismycin A (10, 11.2 mg) was 
obtained as a white crystal from 70% MeOH fraction. The 60% MeOH fraction was subjected 
to HPLC (ODS) and eluted with 45% aqueous MeOH, containing 0.05% TFA at a flow rate of 
2 mL/min. Bamicetin (8, 20.5 mg), streptcytosines B (2, 3.2 mg), C (3, 7.2 mg) and D (4, 8.1 
mg), de-amosaminyl-cytosamine (6, 12.0 mg) and streptcytosine E (5, 5.1 mg) eluted at 5.8, 
16.8, 17.7, 19.3, 20.1 and 20.2 min, respectively. Amicetin (9, 25.0 mg), eluted in the 80% 
MeOH fraction, was isolated by similar HPLC separation procedures as the 60% MeOH 
fraction and eluted at 8.5 min. 
Streptcytosine A (1): obtained as a colorless oil; [α]23D
 
+72 (c 0.1, MeOH); UV λmax (0.1 M 
HCl) nm (log ε): 269 (4.24), 276 (4.24), 317 (4.28); IR max (KBr) cm
–1
: 3500–3400, 2920, 
1712, 1677, 1639, 1613, 1385, 1262, 1093, 802; HRFABMS (m/z) found: 631.3110, calcd: 
631.3092 [M + H]
+
 for C30H43N6O9,; 
1
H and 
13
C NMR data in CD3OD, see Table 2-2. 
1
H NMR 
data in DMSO-d6: δ 1.28 (3H, d, 5.9 Hz), 1.38 (3H, d, 6.0 Hz), 1.40 (3H, s), 1.47 (1H, d, 4.8 
Hz), 1.54 (1H, d, 13.4 Hz), 1.75 (1H, dd, 21.0 Hz, 9.7 Hz), 1.99 (1H, d, 8.4 Hz), 2.31 (1H, m), 
2.88 (6H, s), 3.11 (1H, t, 13.8 Hz), 3.30 (1H, td, 9.6 Hz, 3.6 Hz), 3.41 (1H, dd, 9.3 Hz, 3.2 Hz), 
3.66 (2H, m), 3.83 (2H, m), 3.93 (1H, m), 4.93 (1H, d, 3.2 Hz), 5.23 (2H, q, 7.3 Hz), 5.74 (2H, 
10.4 Hz), 7.35 (1H, d, 7.4 Hz), 7.82 (2H, d, 8.4 Hz), 8.12 (2H, d, 4.5 Hz), 8.17 (1H, d, 7.4 Hz), 
8.94 (1H, brs). 
Streptcytosine B (2): obtained as a pale yellow oil; [α]23D +24 (c 0.1, MeOH); UV λmax (0.1 M 
HCl) nm (log ε): 249 (3.94), 338 (4.09); IR max (KBr) cm
–1
: 3500–3400, 2927, 1683, 1646, 
31 
1616, 1576, 1493, 1385, 1247, 1092; HRFABMS (m/z) found: 326.1180, calcd: 326.1175 [M + 
H]
+
 for C14H20N3O4S; 
1
H and 
13
C NMR data, see Table 2-3. 
Streptcytosine C (3): obtained as a pale yellow oil; [α]23D +36 (c 0.1, MeOH); UV λmax (0.1 M 
HCl) nm (log ε): 257 (3.95), 311 (4.18); IR max (KBr) cm
–1
: 3500–3400, 2928, 1683, 1646, 
1613, 1561, 1489, 1385, 1262, 1092; HRFABMS (m/z) found: 308.1619, calcd: 308.1610 [M + 
H]
+
 for C15H22N3O4; 
1
H and 
13
C NMR data, see Table 2-3. 
Streptcytosine (4): obtained as a pale yellow oil; [α]23D +68 (c 0.1, MeOH); UV λmax (0.1 M 
HCl) nm (log ε): 217 (3.96), 263 (4.16), 309 (4.32); IR max (KBr) cm
–1
: 3500–3400, 2937, 
1735, 1674, 1634, 1561, 1492, 1396, 1272, 1095; HRFABMS (m/z) found: 308.1601, calcd: 
308.1610 [M + H]
+
 for C15H22N3O4; 
1
H and 
13
C NMR  data, see Table 2-3. 
Streptcytosine (5): obtained as a pale yellow oil; [α]23D +62 (c 0.1, MeOH); UV λmax (0.1 M 
HCl) nm (log ε): 237 (3.61), 310 (4.04); IR max (KBr) cm
–1
: 3500–3400, 2963, 1720, 1677, 
1624, 1571, 1494, 1383, 1276, 1095; HRFABMS (m/z) found: 310.1763, calcd: 310.1767 [M + 
H]
+
 for C15H24N3O4; 
1
H and 
13
C NMR data, see Table 2-3. 
De-amosaminyl-cytosamine
 
(6): obtained as a colorless oil; [α]23D +34 (c 0.1, MeOH) ; UV 
(0.1 M HCl) λmax nm (log ε) 277 (4.11); IR νmax (KBr) cm
-1
 3500∼3400,  1723, 1683, 1204, 
1095; 
1
H NMR (CD3OD, 400 MHz) δ 8.01 d (7.8 Hz), 6.11 d (7.8 Hz), 5.65 dd (10.5 Hz, 2.1 
Hz), 3.49 m, 3.24 m, 2.15 m, 2.03 m, 1.77 m, 1.64 m, 1.31 d (6.1 Hz). 
13
C NMR (CD3OD, 100 
MHz) δ 161.9, 148.9, 146.4, 95.3, 84.1, 80.7, 71.6, 32.3, 31.0, 18.5; FABMS m/z 226 [M + 
H]
+
. 
Plicacetin (7): obtained as a yellow oil; [α]23D
 
+96 (c 0.1, MeOH); UV λmax (0.1 M HCl) nm 
(log ε) 255 (4.08), 315 (4.17); IR νmax (KBr) cm
-1
 3500∼3400, 1679, 1643, 1605, 1567, 1487, 
1314, 1257, 1202, 1053; 
1
H NMR (CD3OD, 400 MHz) δ 8.2 (d, 7.2 Hz), 7.81 (d, 8.7 Hz), 7.43 
(d, 6.4 Hz), 6.75 (d, 8.7 Hz), 5.76 (d, 8.4 Hz), 5.00 (d, 3.7 Hz), 4.08 m, 3.98 (br t 10.4 Hz), 
3.75 m, 3.57 (dd, 9.1 Hz, 3.8 Hz), 3.43 (td, 9.4 Hz, 4.6 Hz), 3.12 (t, 10.3 Hz), 3.01 s, 2.38 m, 
2.15 (br d, 10.1 Hz), 1.68 (br d, 9.2 Hz), 1.67 m, 1.46 (d, 6.1 Hz), 1.37 (d, 6.1 Hz). FABMS m/z 
518, [M + H]
+
. 
Bamicetin (8): obtained as a pale yellow oil; [α]23D
 
+66 (c 0.1, MeOH); UV λmax (0.1 M HCl) 
nm (log ε) 251 (4.21), 257 (4.21), 321 (4.42); IR νmax (KBr) cm
-1
 3500∼3400, 2934, 1683, 1644, 
1605, 1487, 1404, 1254, 1204, 1136; 
1
H NMR (CD3OD, 400 MHz) δ 8.21 (d, 7.5 Hz), 8.00 (d, 
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8.0 Hz), 7.83 (d, 8.0 Hz), 7.56 (d, 7.5 Hz), 5.78 (d, 8.6 Hz), 5.03 (d, 3.5 Hz), 4.12 (d, 12.0 Hz), 
4.07, m, 3.88 (br t, 10.0 Hz), 3.84 (d, 10.0 Hz), 3.76 m, 3.53 (dd, 9.1 Hz, 3.8 Hz), 3.44 (td, 9.6 
Hz, 3.9 Hz), 2.88 (t, 9.9 Hz), 2.79 s, 2.41 m, 2.17 (br d 10.2 Hz), 1.70 (br d, 10.2 Hz), 1.68 m, 
1.65 s, 1.38 (d, 6.0 Hz); 
13
C NMR (CD3OD, 100 MHz) δ 170.2, 168.4, 164.7, 156.6, 146.7, 
143.7, 130.3, 130.1, 121.3, 98.7, 96.7, 84.6, 78.2, 76.2, 73.6, 68.7, 65.7, 65.3, 64.7, 63.4, 42.3, 
30.8, 27.8, 19.0, 18.7, 18.0; FABMS m/z 605, [M + H]
+
. 
Amicetin (9): obtained as a pale yellow oil; [α]23D
 
+76 (c 0.1, MeOH); UV λmax (0.1 M HCl) 
nm (log ε) 257 (4.05), 323 (4.31); IR νmax (KBr) cm
-1 
3500∼3400, 2934, 1679, 1602, 1484, 
1405, 1306, 1254, 1202, 1136, 1056; 
1
H NMR (CD3OD, 400 MHz) δ 8.19 (d, 7.4 Hz), 7.99 (d, 
8.8 Hz), 7.82 (d, 8.8 Hz), 7.59 (d, 7.4 Hz), 5.78 (d, 7.9 Hz), 5.02 (d, 3.8 Hz), 4.12 (d, 12.0 Hz), 
4.09 m, 3.98 (br. t, 9.8 Hz), 3.85 (d, 12.0 Hz), 3.76 m, 3.57 (dd, 9.4 Hz, 4.3 Hz), 3.44 (td, 9.6 
Hz, 4.0 Hz), 3.12 (t, 10.2 Hz), 3.02 s, 2.40 m, 2.18 (br d 9.1 Hz), 1.71 (br d, 9.1 Hz), 1.69 m, 
1.66 s, 1.47 (d, 6.1 Hz), 1.38 (d, 6.0 Hz); 
13C NMR (100 MHz, CD3OD) δ 170.5, 168.6, 164.9, 
157.3, 146.8, 144.0, 130.5, 130.4, 121.5, 99.0, 96.8, 84.8, 78.4, 76.6, 74.0, 72.1, 68.1, 65.6, 
64.2, 63.7, 42.6, 31.1, 28.1, 19.3, 19.1, 19.0; FABMS m/z 619, [M + H]
+
. 
Collismycin A (10): obtained as a needle crystal; 
1
H NMR (DMSO-d6, 400 MHz) δ 11.75 s, 
8.73 (br d, 1.3 Hz), 8.70 (d, 4.3 Hz), 8.38 (d, 7.9 Hz), 8.00 br s, 7.96 (t, 7.9 Hz), 7.48 (dd, 7.9 
Hz, 6.8 Hz), 4.05 s, 2.34 (br d, 1.3 Hz).
 13
C NMR (DMSO-d6, 100 MHz) δ 167.1, 156.2, 154.7, 
152.9, 149.5, 147.1, 137.6, 124.9, 121.3, 121.0, 103.1, 56.4, 17.8. FABMS m/z 276, [M + H]
+ 
, 
C13H14N3O2S. 
1
H NMR data in CDCl3: δ 2.36 (3H, s), 4.10 (3H, s), 7.32 (1H, dd, 7.7 Hz, 4.4 
Hz), 7.84 (1H, td, 7.8 Hz, 1.5 Hz), 8.04 (1H, s), 8.53 (1H, d, 8.0 Hz), 8.65 (1H, d, 4.0 Hz), 9.08 
(1H, s), 10.06 (1H, brs). 
SF2738C (11): obtained as a pale yellow oil; 
1
H NMR (CD3OD, 400 MHz) δ 8.87 d (4.7), 8.62 
d (7.8), 8.21 td (7.8, 1.4), 8.20 s, 7.74 dd (7.2, 5.2), 5.10 s, 4.36 s, 2.47. FABMS m/z 263, [M + 
H]
+ 
, C13H15N2O2S. 
1
H NMR data in CDCl3: 2.33 (3H, s), 4.12 (3H, s), 4.97 (2H, s), 7.50 (1H, 
dd, 7.1 Hz, 4.8 Hz), 7.88 (1H, s), 7.99 (1H, m), 8.40 (1H, d, 7.7 Hz), 8.84 (1H, d, 4.4 Hz). 
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2.4 Supporting Spectral Data for Compounds 1—11 
 
Figure 2-S1. UV spectrum of streptcytosine A (1). 
 
 
 
 
Figure 2-S2. IR spectrum of streptcytosine A (1) (KBr). 
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Figure 2-S3. Positive FABMS spectrum of streptcytosine A (1). 
 
 
Figure 2-S4. Negative FABMS spectrum of streptcytosine A (1). 
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Figure 2-S5. 
1
H NMR spectrum of streptcytosine A (1) in CD3OD. 
 
 
Figure 2-S6. 
1
H NMR spectrum of streptcytosine A (1) in DMSO-d6. 
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Figure 2-S7. 
13
C NMR and DEPT spectra of streptcytosine A (1) in CD3OD. 
 
 
Figure 2-S8. 
1
H-
1
H COSY spectrum of streptcytosine A (1) in CD3OD. 
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Figure 2-S9. HMQC spectrum of streptcytosine A (1) in CD3OD. 
 
 
 
Figure 2-S10. HMBC spectrum of streptcytosine A (1) in CD3OD. 
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Figure 2-S11. UV spectrum of streptcytosine B (2). 
 
 
Figure 2-S12.
 
IR spectrum of streptcytosine B (2) (KBr). 
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Figure 2-S13. Positive FABMS spectrum of streptcytosine B (2). 
 
 
 
Figure 2-S14. Negative FABMS spectrum of streptcytosine B (2). 
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Figure 2-S15. 
1
H NMR spectrum of streptcytosine B (2) in CD3OD. 
 
 
Figure 2-S16. 
13
C NMR and DEPT spectra
 
of streptcytosine B (2) in CD3OD. 
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Figure 2-S17. 
1
H-
1
H COSY spectrum of streptcytosine B (2) in CD3OD. 
 
 
Figure 2-S18. HMQC spectrum of streptcytosine B (2) in CD3OD. 
 
42 
 
Figure 2-S19. HMBC spectrum of streptcytosine B (2) in CD3OD. 
 
 
Figure 2-S20. UV spectrum of streptcytosine C (3). 
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Figure 2-S21. IR spectrum of streptcytosine C (3) (KBr). 
 
 
 
 
 
 
Figure 2-S22. Positive FABMS spectrum of streptcytosine C (3). 
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Figure 2-S-23. Negative FABMS spectrum of streptcytosine C (3). 
 
 
Figure 2-S24. 
1
H NMR spectrum of streptcytosine C (3) in CD3OD. 
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Figure 2-S25. 
13
C NMR and DEPT spectra
 
of streptcytosine C (3) in CD3OD. 
 
 
Figure 2-S26. 
1
H-
1
H COSY spectrum of streptcytosine C (3) in CD3OD. 
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Figure 2-S27. HMQC spectrum of streptcytosine C (3) in CD3OD. 
 
 
Figure 2-S28. HMBC spectrum of streptcytosine C (3) in CD3OD. 
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Figure 2-S29. UV spectrum of streptcytosine D (4). 
 
 
 
 
Figure 2-S30. IR spectrum of streptcytosine D (4) (KBr). 
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Figure 2-S31. Positive FABMS spectrum of streptcytosine D (4). 
 
 
 
 
 
Figure 2-S32. Negative FABMS spectrum of streptcytosine D (4). 
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Figure 2-S33. 
1
H NMR spectrum of streptcytosine D (4) in CD3OD. 
 
 
Figure 2-S34. 
13
C NMR and DEPT spectra
 
of streptcytosine D (4) in CD3OD. 
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Figure 2-S35. 
1
H-
1
H COSY spectrum of streptcytosine D (4) in CD3OD. 
 
 
Figure 2-S36. HMQC spectrum of streptcytosine D (4) in CD3OD. 
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Figure 2-S37. HMBC spectrum of streptcytosine D (4) in CD3OD. 
 
 
 
Figure 2-S38. UV spectrum of streptcytosine E (5). 
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Figure 2-S39. IR spectrum of streptcytosine E (5) (KBr). 
 
 
 
 
Figure 2-S40. Positive FABMS spectrum of streptcytosine E (5). 
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Figure 2-S41. Negative FABMS spectrum of streptcytosine E (5). 
 
 
Figure 2-S42. 
1
H NMR spectrum of streptcytosine E (5) in CD3OD. 
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Figure 2-S43. 
13
C NMR and DEPT spectra
 
of streptcytosine E (5) in CD3OD. 
 
 
 
Figure 2-S44. 
1
H-
1
H COSY spectrum of streptcytosine E (5) in CD3OD. 
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Figure 2-S45. HMQC spectrum of streptcytosine E (5) in CD3OD. 
 
 
Figure 2-S46. HMBC spectrum of streptcytosine E (5) in CD3OD. 
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Figure 2-S47. UV spectrum of de-amosaminyl-cytosamine (6). 
 
 
Figure 2-S48. IR spectrum of de-amosaminyl-cytosamine (6) (KBr). 
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Figure 2-S49. Positive FABMS spectrum of de-amosaminyl-cytosamine (6). 
 
 
Figure 2-S50. 
1
H NMR spectrum of de-amosaminyl-cytosamine (6) in CD3OD. 
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Figure 2-S51. 
13
C NMR and DEPT spectra
 
of de-amosaminyl-cytosamine (6) in CD3OD. 
 
 
 
Figure 2-S52. 
1
H-
1
H COSY spectrum of de-amosaminyl-cytosamine (6) in CD3OD. 
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Figure 2-S53. HMQC spectrum of de-amosaminyl-cytosamine (6) in CD3OD. 
 
 
 
Figure 2-S54. HMBC spectrum of de-amosaminyl-cytosamine (6) in CD3OD. 
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Figure 2-S55. UV spectrum of plicacetin (7). 
 
 
 
 
 
Figure 2-S56.  IR spectrum of plicacetin (7) (KBr). 
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Figur
e 2-S57.  Negative FABMS spectrum of plicacetin (7). 
 
 
Figure 2-S58. 
1
H NMR spectrum of plicacetin (7) in CD3OD. 
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Figure 2-S59. 
1
H-
1
H COSY spectrum of plicacetin (7) in CD3OD. 
 
 
Figure 2-S60. HMQC spectrum of plicacetin (7) in CD3OD. 
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Figure 2-S61. HMBC spectrum of plicacetin (7) in CD3OD. 
 
 
 
 
Figure 2-S62. UV spectrum of bamicetin (8). 
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Figure 2-S63. IR spectrum of bamicetin (8) (KBr). 
 
 
 
 
Figure 2-S64. Positive FABMS spectrum of bamicetin (8). 
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Figure 2-S65. 
1
H NMR spectrum of bamicetin (8) in CD3OD. 
 
 
 
Figure 2-S66. 
13
C NMR and DEPT spectra
 
of bamicetin (8) in CD3OD. 
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Figure 2-S67.
 1
H-
1
H COSY spectrum of bamicetin (8) in CD3OD. 
 
 
 
Figure 2-S68. HMQC spectrum of bamicetin (8) in CD3OD. 
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Figure 2-S69. HMBC spectrum of bamicetin (8) in CD3OD. 
 
 
 
Figure 2-S70. UV spectrum of amicetin (9). 
 
 
68 
 
 
 
 
Figure 2-S71. IR spectrum of amicetin (9) (KBr). 
 
 
 
Figure 2-S72. Positive FABMS spectrum of amicetin (9). 
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Figure 2-S73. Negative FABMS spectrum of amicetin (9). 
 
 
Figure 2-S74. 
1
H NMR spectrum of amicetin (9) in CD3OD. 
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Figure 2-S75.
 13
C NMR and DEPT spectra
 
of amicetin (9) in CD3OD. 
 
 
 
Figure 2-S76.
 1
H-
1
H COSY spectrum of amicetin (9) in CD3OD. 
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Figure 2-S77. HMQC spectrum of amicetin (9) in CD3OD. 
 
 
Figure 2-S78. HMBC spectrum of amicetin (9) in CD3OD. 
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Figure 2-S79. EIMS spectrum of collismycin A (10). 
 
 
Figure 2-S80. 
1
H NMR spectrum of collismycin A (10) in DMSO-d6. 
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Figure 2-S81. 
1
H NMR spectrum of collismycin A (10) in CDCl3. 
 
 
 
Figure 2-S82. 
13
C NMR and DEPT spectra of collismycin A (10) in DMSO-d6. 
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Figure 2-S83. 
1
H-
1
H COSY spectrum of collismycin A (10) in DMSO-d6. 
 
 
 
Figure 2-S84. HMQC spectrum of collismycin A (10) in DMSO-d6. 
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Figure 2-S85. HMBC spectrum of collismycin A (10) in DMSO-d6. 
 
 
Figure 2-S86. Positive FABMS spectrum of SF2738C (11). 
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Figure 2-S87. 
1
H NMR spectrum of SF2738C (11) in CD3OD. 
 
 
Figure 2-S88. 
1
H NMR spectrum of SF2738C (11) in CDCl3. 
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3. Isolation and Characterization of New Pyrone-Type Polyketides from a 
Marine-Derived Penicillium sp. TPU1271 
3.1 Introduction  
Marine sources provided numbers of biologically active compounds, including anti-tumor, 
anti-cancer, anti-microtubule, anti-proliferative, cytotoxic, photo protective, as well as 
antibiotic and antifouling properties (Bhatnaga, I., 2010). Marine microorganisms, especially 
marine-derived fungi, have become an important source of pharmacologically active 
metabolites (Bugni, T. S., 2004). Compounds from marine-derived fungi have been recognized 
as one of the richest sources of structurally novel and biologically active metabolites (Jensen, P. 
R.; Fenical, W., 2000). 
In the course of our continuous search for new compounds produced by marine-derived 
fungi, a marine-derived Penicillium sp. (strain TPU1271) was found to produce various types 
of secondary metabolites, including pyrone-type and acetylenic-type polyketides, 
diketopiperazines, quinoline alkaloids, benzodiazepines, cyclic dipeptides and sesquiterpenoids. 
Further isolation from the culture broth of Penicillium sp. TPU1271 obtained two new 
pyrone-type polyketides, compound (12a) and 9-epi-compound (13a) (Figure 3-1), along with 
nine known compounds, verrucosidin (14) (Wilson, B. J., 1981) (Burka, L. T. 1983) (Hodge, R. 
P., 1988), fructigenine A (15) (Arai, K., 1989) (Kozlovsky, A. G., 2001), verrucofortine (16) 
(Hodge, R. P., 1988) (Arai, K., 1989) , cyclopenol
 
(17) (Birkinshaw, J. H.,1963), cyclopenin 
(18) (Bracken, A., 1954), penipratynolene (19) (Nakahara, S., 2004) (Jian, Y. J., 2010), 
cyclo-(L-Trp- L-Phe) (20) (Kimura, Y., 1996) (Chu, D., 2011), aspterric acid (21) (Shimada, A., 
2002) and viridicatol (22) (Birkinshaw, J. H.,1963) (Yurchenko, A. N., 2010). In this study, the 
isolation, structural determination and antimicrobial activity of compound (12a), 
9-epi-compound (13a) and their acetate derivatives (12b) and (13b) are described.  
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Figure 3-1. Structures of new compounds 12a, 13a and their acetates 12b, 13b 
 
 
 
 
Figure 3-2. Structures of known compounds 14−22. 
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3.2 Results and Discussion 
The Penicillium sp. strain TPU1271 was isolated from the organic matter attached with 
cultivating oysters collected at the Oshika Peninsula, Miyagi Prefecture, Japan (Figure 3-3). The 
crude extracts of the whole broth were absorbed on ODS silica gel and subjected to the column 
chromatography. The elutes were further separated by preparative HPLC to yield two new 
polyketides, compound (12a) and 9-epi-compound (13a), and nine known compounds. The 
structures of known compounds 14−22 were determined on the basis of their spectroscopic data 
and comparison with the reported values for verrucosidin (14) (Wilson, B. J., 1981) (Burka, L. T. 
1983) (Hodge, R. P., 1988), fructigenine A (15) (Arai, K., 1989) (Kozlovsky, A. G., 2001), 
verrucofortine (16) (Hodge, R. P., 1988) (Arai, K., 1989) , cyclopenol
 
(17) (Birkinshaw, J. 
H.,1963), cyclopenin (18) (Bracken, A., 1954), penipratynolene (19) (Nakahara, S., 2004) (Jian, 
Y. J., 2010), cyclo-(L-Trp- L-Phe) (20) (Kimura, Y., 1996) (Chu, D., 2011), aspterric acid (21) 
(Shimada, A., 2002) and viridicatol (22) (Birkinshaw, J. H.,1963) (Yurchenko, A. N., 2010). 
 
 
Figure 3-3.  Sampling side of marine-derived fungi (2012) 
 
 
 
● 
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3.2.1 Isolation of Compounds 
The producing fungus was cultured on a liquid medium for 21 days. The culture was 
added a half volume of cetone and filtered. After the evaporation of acetone, the filtrate was 
separated with an ODS column followed by repeated HPLC (ODS) to obtain compounds 12a, 
13a and 14－22 (Figure 3-4). 
 
 
Penicillium sp. (strain TPU1271) 
    seed culture (30 mL, 27℃, 150 r.p.m, 3 days)  
    main culture (3.0 L, RT, static, 21 days) 
broth 
     added acetone and filtered 
 filtrate 
evaporate acetone 
     absorbed on an ODS column 
MeOH (%)             eluted with a stepwise gradient of H2O/MeOH 
     
 Fr.3 (40 %)         Fr.5 (60 %)               Fr.7 (80 %)       Fr.8 (90%)  
          (200.2 mg)         (171.4 mg)              (181.4 mg)        (70.5 mg )  
                                                              
                                                             
 
 
 
 
 
Figure 3-4. Isolation procedure for the whole broth extract of strain TPU1271. 
 
 
 
 
14 (17.5 mg)  
MPLC-LH20  
30 % MeOH                                           
12a    13a      18     19     20     22  
(5.5 mg) (4.1 mg) (11.2 mg) (2.4 mg) (2.3 mg) (5.5 mg)                                                
17 (90.0 mg) 
HPLC-ODS  
50 % MeOH                                    
HPLC-ODS
70 % MeOH                                          
HPLC-ODS  
80 % MeOH                                          
15      16     21 
(2.6 mg) (19.0 mg) (80.5 mg) 
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3.2.2 Structure Determination of New Compounds  
Compound 12a was obtained as colorless oils. The molecular weight and formula, 434 
and C24H34O7, were deduced from HRFABMS and NMR data. The 
1
H NMR spectrum of 12a 
showed nine sp
3 
methyl, two olefin sp
2 
methane and three oxygenated sp
3 
methine signals and 
suggested the presence of two activated hydrogens. The 
1
H and 
13
C NMR signals were 
assigned by the analysis of 
1
H-
1
H COSY, HMQC and HMBC data (Table 3-1). 
1
H-
1
H COSY 
data revealed the partial structures I and II and their connectivity in compound 12a was 
established by the analysis of HMBC correlations.(Figure 3-5) 
Compound 12a was a geometric isomer of verrucosidinol (Yu, K., 2010) at C-7 to 9 and 
they had similar 
1
H NMR and 
13
C NMR data (Table 3-1). The chemical shifts and coupling 
constants of the α-pyrone and furan units were very similar to those of verrucosidinol (Yu, K., 
2010). The differences between the structures of compound 12a and verrucosidinol were the 
types of heptadiene units (Figure 3-5). The heptadiene unit of compound 12a was revealed to 
connect with the furan unit by the analysis of HMBC correlations from H-11 to C-12 and C-13 
and from H-23 to C-11 (Figure 3-5). The connectivity of the heptadiene unit to α-pyrone unit 
was confirmed by HMBC correlations from H-20 to C-5 and from H-7 to C-5. Therefore, the 
gross structure of compound 12a was established (Figure 3-5).    
 
Compound 13a had the same molecular formula and weight as 12a, which was deduced 
from the analysis of HRFABMS and NMR data. The 
1
H and 
13
C NMR signals were assigned 
by the analysis of 
1
H-
1
H COSY, HMQC and HMBC data (Table 3-1). The 
1
H and 
13
C NMR 
signals were very close to those of compound 12a (Table 3-1). Compound 13a had the same 
1
H-
1
H COSY, HMQC and HMBC data as 12a and the skeletal structure of compound 13a was 
established as the same as 12a (Figure 3-5).  
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Table 3-1. 
13
C (100 MHz) and 
1
H (400 MHz) NMR data (CD3OD) for compounds 12a, 13a. 
 
12a 
 
13a 
C# δC,    δH, mult. (J in Hz)   δC,    δH, mult. (J in Hz) 
1 167.7  
   
167.7  
  
2 110.9  
   
110.9  
  
3 171.9  
   
171.9  
  
4 113.4  
   
113.3  
  
5 162.8  
   
162.8  
  
6 75.3  
   
75.3  
  
7 133.8  
 
5.88, t (1.2) 
 
134.1  
 
5.86, t (1.2) 
8 137.7  
   
137.8  
  
9 82.6  
 
4.23, s 
 
82.6  
 
4.24, s 
10 139.7  
   
139.8  
  
11 130.3  
 
5.70, t (1.5) 
 
129.9  
 
5.69, t (1.2) 
12 81.7  
   
81.7  
  
13 68.9  
 
3.55, s 
 
68.89 
 
3.54, s 
14 68.8  
   
68.86 
  
15 78.4  
 
4.03, q (6.8) 
 
78.4  
 
4.03, q (6.9) 
16 19.4  
 
1.14, d (6.8) 
 
19.4  
 
1.13, d (6.9) 
17 10.3  
 
2.02, s 
 
10.3  
 
2.02, s 
18 61.3  
 
3.85, s 
 
61.3  
 
3.85, s 
19 11.1  
 
2.10, s 
 
11.1  
 
2.09, s 
20 27.9  
 
1.63, s 
 
28.0  
 
1.64, s 
21 13.1  
 
1.33, overlapped s 
 
13.1  
 
1.33, br d (1.0) 
22 14.4  
 
1.70, br d (1.2) 
 
14.7  
 
1.71, d (1.2) 
23 22.1  
 
1.33, overlapped s 
 
22.1  
 
1.32, s 
24 13.9    1.43, s   13.8    1.42, s 
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Figure 3-5. 
1
H-
1
H COSY and key HMBC correlations of compounds 12a. 
 
The relative configurations of compounds 12a and 13a were determined by the analysis of 
NOESY correlations of their acetate derivatives 12b and 13b (Figure 3-6). From the NOESY 
correlations of 12b and 13b, a 9S*-configuration in compound 12a and a 9R*-configuration in 
compound 13a were determined, respectively (Figure 3-6).     
 
 
Figure 3-6. NOESY correlations of compounds 12b and 13b. 
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3.2.3 Structure Determination of Known Compounds 
Compound 14 was obtained as a pale yellow oil. The molecular weight and formula, 416 
and C24H32O6, were deduced from EIMS and NMR data. The 
1
H NMR spectrum of 14 showed 
nine sp
3 
methyl, two olefin sp
2 
methane and three oxygenated sp
3 
methine signals, which could 
be confirmed that compound 14 had no activated hydrogens. The planer structure of compound 
14 was determined by HMBC, HMQC and 
1
H-
1
H COSY correlations. The absolute 
configuration of compound 14 was considered as the same as the known compound 
verrucosidin by comparing the chemical shifts with those reported values. Therefore, the 
structure of compound 14 was determined.  
Compound 15 was obtained as a yellow oil. The molecular weight and molecular formula, 
443 and C27H29N3O3, were decided by the analysis of 1H and 13C NMR spectra and EIMS data. 
The 
1
H NMR in CDCl3 showed 29 signals. From 
1
H NMR spectrum, germinal methyl (δ 0.88 
and 1.03 ppm), terminal olefin (δ 5.02, d, J = 17.5 Hz; δ 5.04, d, J=10.8 Hz and δ 5.67, dd, 
J=17.3 Hz, 11.0 Hz) could be confirmed. The structure of compound 15 was determined by 
HMBC, HMQC and 
1
H-
1
H COSY correlations. Further comparison of 
1
H and 
13
C NMR data 
for 15 with the reported values for fructigenin A confirmed the structure of 15. 
Compound 16 was obtained as a yellow oil. The molecular weight and molecular formula, 
409 and C24H31N3O3, were decided by the analysis of 1H and 13C NMR spectra and EIMS data. 
The 
1
H NMR spectrum of compound 16 was similar to that of fructigenine A. The difference 
between 15 and 16 was detected at the side chain, that is, compound 16 had an isopropyl group 
instead of the phenyl group in 15. The 
1
H NMR spectrum of compound 16 was very close to 
that of verrucofortine as reported. Thus, compound 16 was identified as a known compound. 
Compound 17 was obtained as a pale yellow powder. The molecular weight and 
molecular formula, 310 and C17H14N2O4, were decided by the analysis of 1H and 13C NMR 
spectra and EIMS data. Compound 18 was obtained as a pale yellow oil. Compound 18 had the 
molecular weight and molecular formula of 294 and C17H14N2O3. From 
1
H NMR spectrum of 
compound 18, a bezene ring was confirmed in the field of δ 7.0-7.6 Hz. The molecular weight 
of compound 17 was 16 (O) more than that of compound 18. A hydroxyl group was considered 
to be attached to the benzene ring, and compound 17 and 18 were confirmed as cyclopenol, 
cyclopenin, respectively. 
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Compound 19 was obtained as a colorless oil. The molecular weight and molecular 
formula of 220 and C12H12O4 were decided from 1D NMR and EIMS data. The signals due to a 
methoxy proton signal (δ 3.81) and one 1,4-di-substituted phenyl group were observed in the 
1
H NMR specturm. The structure of 19 was established by HMBC correlations and was 
confirmed as penipratynolene. 
Compound 20 was obtained as a white powder. The molecular weight and molecular 
formula of 333 and C20H19N3O2 were decided from 1D NMR and EIMS data. The 
1
H NMR 
spectrum of compound 20 showed that 20 was a diketopiperazine. The structure of compound 
20 was decided by HMBC correlations and confirmed as cyclo-(L-Trp- L-Phe).  
Compound 21was obtained as a brown powder. EIMS showed a peak at m/z 266, and the 
molecular formula of C15H22O4 was decided by the analysis of 1D NMR spectrum. The 
structure of compound 21 was decided by 
1
H-
1
H COSY, HMQC and HMBC correlations and 
was confirmed as aspterric acid (21) 
Compound 22 was obtained as a pale orange oil. The molecular weight of 253 was 
determined by EIMS. The molecular formula (C15H11O3N) of compound 22 was decided from 
1
H and 
13
C NMR data. All the signals of 
1
H and 
13
C NMR were in the lower-field region. The 
structure of compound 22 was decided by 
1
H-
1
H COSY, HMQC and HMBC correlations. 
Compound 22 was identified as viridicatol. 
3.2.4 Biological Activity  
The antibacterial activity against M. smegmatis NBRC 3207 of compounds 12a, 12b, 13a, 
13b and 14−22 were evaluated by the paper disc method (Ericsson, H., 1960). Only 
verrucosidin (14) showed modest activity (11 mm at 40 μg/disc). Verrucosidin (14), acting as a 
potent neurotoxin to the mammal animals, was first isolated from the fungus Penicillium 
verrucosum var. cyclopium (Wilson, B. J., 1981), and reported to inhibit dose-dependently the 
expression of GRP78 promoter with the IC50 value of 25 nM (Choo, S. J., 2005). In this study, 
verrucosidin (14) was first reported to show anti-mycobacterial activity against M. smegmatis. 
Although new compounds 12a, 13a and their acetates 12b, 13b showed no activity against 
M. smegmatis, these compounds have close structural relationship to the polyene α-pyrone 
mycotoxins, such as verrucosidin (14) and citreoviridin (Sakabe, N., 1964), most of which 
showed potent inhibitory activity against mitochondrial ATPase and oxidative phosphorylation 
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(Whang, K., 1990). 
 
3.3 Experimental Section 
3.3.1 General Experimental Procedures  
NMR spectral data were obtained by a JEOL JNM-AL-400 NMR spectrometer (JEOL 
Ltd., Japan; 400 MHz for 
1
H and 100 MHz for 
13
C) in CD3OD (δH 3.31, δC 49.15), CDCl3 (δH 
7.24, δC 77.23), acetone-d6 (δH 2.05, δC 29.92, 206.68) and DMSO-d6 (δH 2.50, δC 39.51). Mass 
spectra were recorded with a JEOL JMS-MS 700 mass spectrometer (EI or FAB mode with 
m-nitrobenzyl alcohol or glycerol as the matrix). UV spectra were obtained on a Hitachi 
U-3310 UV-Visible spectrophotometer (Hitachi, Ltd., Japan) and IR spectra on a PerkinElmer 
Spectrum One Fourier transform infrared spectrometer (Waltham, MA, USA). Optical 
rotations were measured with a JASCO P-2300 digital polarimeter (JASCO, Ltd., Japan). 
Preparative HPLC was conducted using a Toyosoda CCPU instrument equipped with a Tosoh 
UV-8010 detector. 
 
3.3.2 Isolation, Identification, and Fermentation of Producing Bacterium 
The fungus strain, TPU1271, was isolated from the organic matter attached with 
cultivating oysters collected at a depth of 10 meters under the seawater at the Oshika Peninsula, 
Miyagi Prefecture, Japan in June, 2012. The organic matter was diluted 25 times with sterile 
seawater and 200 μL of the resulted liquid was plated to an agar medium (PDA, 90% seawater). 
The isolated fungus was identified as Penicillium sp. relied on morphological and gross 
physiological characters.  
The single colony of strain TPU1271 grown on the PDA was inoculated into a 100-mL 
Erlenmeyer flask containing 40 mL of the seed medium (2% glucose, 0.5% polypeptone, 
0.05% MgSO4·7H2O, 0.2% yeast extract, 0.1% KH2PO4, 0.1% agar and seawater, pH 6.0). The 
flask was shaken for 3 days at 25 ℃, and 2 mL of the culture broth was transferred into 
500-mL Erlenmeyer flasks containing each 200 mL of the production medium (3% sucrose, 
3% soluble starch, 1% malt extract, 0.3% Ebios (Asahi Food & Healthcare Co. Ltd., Tokyo, 
Japan), 0.5% KH2PO4 and 0.05% MgSO4·7H2O and natural seawater, pH 6.0). Fifteen 500-mL 
Erlenmeyer-flasks were cultured and maintained static at room temperature for 3 weeks. 
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Figure 3-7. Picture of marine-derived Penicillium sp. TPU1271 grown on an agar plate. 
 
3.3.3 Bioassay 
Compounds 12a, 12b, 13a, 13b and 14−22 were tested for antimicrobial activity against 
Mycobacterium smegmatis NBRC 3207 (48 hours at 37℃). A sterile antibiotic filter disc (6 
mm in diameter), treated with the test sample was placed in the dish. After incubation, the 
inhibition zone in diameter (mm) was measured. 
 
3.3.4 Extraction and Isolation of New Polyketides 
The whole broth (3 L) was added an equal amount of acetone and filtered. The mixture 
was evaporated under reduced pressure to remove acetone, and the aqueous solution was 
subjected to ODS column chromatography. The column was eluted with a stepped gradient of 
H2O-MeOH mixtures (100:0 to 0:100, v/v) to obtain 10 fractions. Compound (12a, 5.5 mg), 
compound (13a, 4.1 mg), cyclopenin (18, 11.2 mg), penipratynolene (19, 2.4 mg)， 
cyclo-(L-Trp- L-Phe) (20, 2.1 mg) and viridicatol (22, 5.5 mg) were obtained by separation of 
the 50% MeOH fraction with preparative reversed-phase HPLC (Senshu Scientific Co., Ltd., 
Pegasil ODS SP100 column, 250 × 10 mm, 5 μm; MeOH-H2O=50:50; 2.0 mL/min; UV 210 
nm). Fructigenine A (15, 19.0 mg), verrucofortine (16, 2.6 mg) and aspterric acid (21, 80.5 mg) 
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were isolated from 70% MeOH fraction with the same HPLC systems (MeOH-H2O=70:30; 2.0 
mL/min; UV 210 nm). Verrucosidin (14, 17.5 mg) were purified with HPLC separation by 
eluting with the solution of MeOH-H2O=80:20. The 30% MeOH fraction was 
chromatographed on a Sephadex LH-20 column with MeOH-H2O=30:70 to yield cyclopenol 
(17, 90.0 mg).  
Compound (12a): [α]20D
 +110 (c 0.1, MeOH) ; UV λmax (MeOH) nm (log ε): 306 (3.40), 394 
(1.25); IR νmax (KBr) cm
-1
:
 
2978, 2929, 2857, 1688, 1558, 1451, 1377, 1095, 1043, 1012; 
HRFABMS (m/z) found: 435.2389, calcd: 435.2383 [M + H]
+ 
for C24H35O7; 
1
H and 
13
C NMR 
data in CD3OD, see Table 3-1;  
12a-acetate (12b): [α]21D
 
+122 (c 0.1, MeOH) ; UV λmax (MeOH) nm (log ε): 300 (3.97), 368 
(0.82), 387 (1.25), 394 (1.69); IR νmax (KBr) cm
-1
:
 
2973, 2929, 1739, 1714, 1690, 1561, 1454, 
1372, 1355, 1237, 1089, 1043, 1029; HRFABMS (m/z) found: 477.2492, calcd: 477.2488 [M + 
H]
+ 
for C26H37O8; 
1
H NMR data in CD3OD: δ 5.84 (1H, t, 0.9 Hz, H-7), 5.32 (1H, s, H-9), 5.65 
(1H, t, 0.9 Hz, H-11), 3.54 (1H, s, H-13), 4.02 (1H, q, 6.8 Hz, H-15), 1.11 (3H, d, 6.8 Hz, 
H-16), 2.018 (3H, s, H-17), 3.85 (3H, s, H-18), 2.08 (3H, s, H-19), 1.61 (3H, s, H-20), 1.39 
(3H, br d, 1.0 Hz, H-21), 1.76 (3H, br d, 0.7 Hz, H-22), 1.30 (3H, s, H-23), 1.41 (3H, s, H-24), 
2.05 (3H, s, H-26). 
Compound (13a): [α]20D
 +96 (c 0.1, MeOH) ; UV λmax (MeOH) nm (log ε): 304 (3.63), 393 
(1.43); IR νmax (KBr) cm
-1
:
 
2978, 2934, 2863, 1683, 1558, 1451, 1380, 1092, 1048, 1026; 
HRFABMS (m/z) found: 435.2391, calcd: 435.2383 [M + H]
+ 
for C24H35O7; 
1
H and 
13
C NMR 
data in CD3OD, see Table 3-1;  
13a-acetate (13b): [α]21D
 
+118 (c 0.1, MeOH) ; UV λmax (MeOH) nm (log ε): 297 (3.85), 386 
(1.80), 397 (1.29); IR νmax (KBr) cm
-1
:
 
2978, 2934, 1742, 1714, 1690, 1561, 1451, 1372, 1353, 
1235, 1089, 1078, 1040, 1026; HRFABMS (m/z) found: 477.2498, calcd: 477.2488 [M + H]
+ 
for C26H37O8; 
1
H NMR data in CD3OD: δ 5.82 (1H, t, 0.9 Hz, H-7), 5.30 (1H, s, H-9), 5.67 (1H, 
t, 0.9 Hz, H-11), 3.55 (1H, s, H-13), 4.02 (1H, q, 6.8 Hz, H-15), 1.11 (3H, d, 6.8 Hz, H-16), 
2.020 (3H, s, H-17), 3.85 (3H, s, H-18), 2.08 (3H, s, H-19), 1.62 (3H, s, H-20), 1.38 (3H, br d, 
1.0 Hz, H-21), 1.76 (3H, br d, 0.7 Hz, H-22), 1.30 (3H, s, H-23), 1.42 (3H, s, H-24), 2.024 (3H, 
s, H-26). 
Verrucosidin (14): obtained as a pale yellow oil. [α]22D
 
+70 (c 0.1, MeOH); EIMS (m/z) 416; 
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1
H NMR data in CDCl3: δ 1.16 (3H, d, 6.8 Hz), 1.39 (3H, s), 1.40 (3H,s), 1.44 (3H, s), 1.87 
(3H, brs), 1.93 (3H, brs), 2.01 (3H, s), 2.02 (3H, s), 3.40 (1H, s), 3.46 (1H, s), 3.80 (3H, s), 
4.10 (1H, q, 6.8 Hz), 5.44 (1H, s), 5.83 (1H, s). 
Fructigenine A (15): obtained as a yellow oil; EIMS (m/z) at 443; Molecular formula: 
C27H29N3O3; 
1
H NMR data in CDCl3: δ 0.88 (3H, s), 1.03 (3H, s), 2.14 (1H, t, 12.0 Hz), 2.46 
(1H, dd, 5.6 Hz), 2.57 (3H, s), 2.74 (1H, dd, 14.4 Hz, 9.4 Hz), 3.44 (1H, dd, 14.3 Hz, 3.5 Hz), 
3.70 (1H, dd, 10.3 Hz, 5.0 Hz), 4.15 (1H, dd, 10.1 Hz, 2.3 Hz), 5.02 (1H, d, 17.5 Hz), 5.04 (1H, 
d, 10.8 Hz), 5.67 (1H, dd, 17.3 Hz, 11.0 Hz), 5.74 (1H, brs, exchangeable with D2O), 5.95 (1H, 
brs), 7.02-7.27 (8H, m), 7.93 (1H, brs). 
Verrucofortine (16): obtained as a yellow oil; EIMS (m/z) at 409; Molecular formula: 
C24H31N3O3; 
1
H NMR data in DMSO-d6: δ 0.83 (3H, d, 6.8), 0.85 (3H, d, 6.8), 0.88 (3H, s), 
1.06 (3H, s), 1.72 (1H, m), 1.76 (1H, m), 1.84 (1H, m), 2.26 (1H, t, 12 Hz), 2.55 (3H, s), 3.18 
(2H, d, 4.8 Hz), 3.80 (1H, dd, 11.3 Hz, 6.0 Hz), 4.03 (1H, m), 5.06 (1H, d, 10.2 Hz), 5.10 (1H, 
d, 16.1 Hz), 5.87 (1H, dd, 11.0 Hz, 10.2 Hz), 5.97 (1H, brs), 7.17 (1H, t, 7.3), 7.30 (1H, t, 7.6 
Hz), 7.47 (1H, d, 7.6), 7.84 (1H, d, 8.0 Hz), 8.11 (1H, brs);
 1
H NMR data in CDCl3: δ 0.88 (3H, 
6.6), 0.97 (3H×2, d, 6.2), 1.13 (3H, s), 1.55 (1H, m), 1.73 (1H, m), 1.99 (1H, m), 2.38 (1H, dd, 
11,7 Hz, 8.5 Hz), 2.60 (1H, d, 6.3 Hz), 2.61 (3H, s), 3.85 (1H, m), 3.94 (1H, m), 5.09 (1H, 
d,17.9 Hz), 5.10 (1H, d, 10.6 Hz), 5.77 (1H, m), 5.98 (1H, brs), 7.13 (1H, t, 7.0 Hz), 7.27 (1H, 
m), 7.30 (1H, d, 7.3 Hz), 7.98 (1H, brs). 
Cyclopenol
 
(17): obtained as a yellow powder; EIMS (m/z) at 310; Molecular formula: 
C17H14N2O4; 
1
H NMR data in CD3OD: δ 3.19 (3H, s), 4.08 (1H, s), 6.10 (1H, d, 7.3), 6.15 (1H, 
t, 2.2), 6.71 (1H, br d, 8.0 Hz), 7.01 (1H, t, 8.0), 7.15-7.18 (1H×3, m), 7.55 (1H, m).
 1
H NMR 
data in acetone-d6: δ 3.13 (3H, s), 4.12 (1H, s), 6.1-6.3 (2H, m), 6.7-7.6 (6H, m), 8.42 (1H, brs), 
9.66 (1H, brs). 
Cyclopenin (18): obtained as a pale yellow oil; EIMS (m/z) at 294; Molecular formula: 
C17H14N2O3; 
1
H NMR data in CD3OD: δ 3.16 (3H, s), 4.15 (1H, s), 6.66 (1H×2, d, 7.6 Hz), 
7.02 (1H, dd, 8.0 Hz, 0.8 Hz), 7.13 (1H×2, m), 7.19 (1H×2, br d, 7.8), 7.27 (1H, t, 7.4), 7.53 
(1H, td, 5.9 Hz, 1.5 Hz).
 1
H NMR data in CDCl3: δ 3.22 (3H, s), 3.98 (1H, s), 6.6-6.7 (2H, m), 
7.0-7.6 (7H, m), 8.82 (1H, brs). 
Penipratynolene (19): obtained as a colorless oil; EIMS (m/z) at 220; Molecular formula: 
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C12H12O4; 
1
H NMR data in DMSO-d6: δ 3.42 (1H, d, 2.2 Hz), 3.81 (3H, s), 4.08 (2H, m), 4.59 
(1H, ddd, 8.3, 6.6 Hz, 2.2 Hz), 5.87 (1H, d, 6.1 Hz), 7.07 (2H, d, 9.1), 7.91 (2H, d, 9.1). 
1
H 
NMR data in acetone-d6: δ 2.98 (1H, d, 2.0 Hz), 3.84 (3H, s), 4.19 (2H, m), 4.75 (1H, m), 4.91 
(1H, brs), 7.07 (2H, d, 8.9 Hz), 7.97 (2H, d, 8.9 Hz). 
Cyclo-(L-Trp-L-Phe) (20): obtained as a white powder; EIMS (m/z) at 333; Molecular 
formula: C20H19N3O2; 
1
H NMR data in DMSO-d6: δ 1.85 (1H, dd, 13.6 Hz, 6.9 Hz), 2.45 (1H, 
dd, 13.2 Hz, 4.6 Hz), 2.52 (1H, dd, 14.3 Hz, 5.9 Hz), 2.80 (1H, dd, 14.5 Hz, 4.3 Hz), 3.85 (1H, 
m), 3.97 (1H, m), 6.71 (2H, m), 6.96 (1H, d, 2.4 Hz), 7.00 (1H, m), 7.07 (1H, t, 7.0 Hz), 7.17 
(1H, m), 7.32 (1H, d, 7.5 Hz), 7.49 (1H, d, 7.9 Hz), 7.71 (1H, d, 2.0 Hz), 7.92 (1H, d, 1.8 Hz), 
10.90 (1H, s). 
Aspterric acid (21): obtained as a brown powder; EIMS (m/z) at 266;
 
Molecular formula: 
C15H22O4; 
1
H NMR data in DMSO-d6: 1.53 (1H, m), 1.61 (1H, m), 1.72 (3H, s), 1.77 (1H, m), 
1.80 (1H, m), 1.85 (3H, s), 2.13 (1H, brs), 2.16 (1H, brs), 2.28 (1H, m), 2.42 (1H, dd, 14.7 Hz, 
8.7 Hz), 2.53 (1H, br d, 11.9 Hz), 3.48 (1H, d, 1.1 Hz), 3.82 (1H, d, 8.1 Hz), 4.43 (1H, d, 8.4 
Hz); 
1
H NMR data in CDCl3: δ 1.52 (1H, m), 1.59 (3H, s), 1.70 (3H, s), 1.73 (1H, m), 1.74 (1H, 
m), 2.03 (1H, m), 2.14 (1H, m), 2.18 (1H, m), 2.27 (1H, m), 2.3-2.4 (3H, m), 2.41 (1H, m), 
3.50 (1H, d, 8.4 Hz), 3.92 (1H, d, 8.4 Hz), 4.28 (1H, d, 8.5 Hz). 
Viridicatol (22): obtained as a pale orange oil; EIMS (m/z) at 253;
 
Molecular formula: 
C15H11O3N; 
1
H NMR data in DMSO-d6: δ 6.71 (1H, m), 6.72 (1H, m), 6.82 (1H, m), 7.07 (1H, 
m), 7.10 (1H, m), 7.29 (1H, t, 7.4), 7.31 (1H, m), 7.32 (1H, m), 9.14 (1H, s), 9.54 (1H, s), 
12.21 (1H, s). 
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3.4 Supporting Spectral Data for Compounds 12a, 12b, 13a, 13b and 14−22 
 
 
Figure 3-S1. UV spectrum of compound (12a). 
 
 
 
Figure 3-S2. IR spectrum of compound (12a).  
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Figure 3-S3. Positive FABMS spectrum of compound (12a).  
 
 
 
Figure 3-S4. 
1
H NMR spectrum of compound (12a) in CD3OD. 
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Figure 3-S5. 
13
C NMR and DEPT spectra of compound (12a) in CD3OD. 
 
 
Figure 3-S6. 
1
H-
1
H COSY spectrum of compound (12a) in CD3OD. 
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Figure 3-S7. HMQC spectrum of compound (12a) in CD3OD. 
 
 
Figure 3-S8. HMBC spectrum of compound (12a) in CD3OD. 
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Figure 3-S9. UV spectrum of 12a-acetate (12b). 
 
 
 
Figure 3-S10. IR spectrum of 12a-acetate (12b). 
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Figure 3-S11. MS spectrum of 12a-acetate (12b). 
 
 
Figure 3-S12. 
1
H NMR spectrum of 12a-acetate (12b). 
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Figure 3-S13. UV spectrum of compound (13a). 
 
 
 
Figure 3-S14. IR spectrum of compound (13a).  
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Figure 3-S15. Positive FABMS spectrum of compound (13a).  
 
 
 
 
Figure 3-S16. 
1
H NMR spectrum of compound (13a) in CD3OD. 
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Figure 3-S17. 
13
C NMR and DEPT spectra of compound (13a) in CD3OD. 
 
 
Figure 3-S18. 
1
H-
1
H COSY spectrum of compound (13a) in CD3OD. 
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Figure 3-S19. HMQC spectrum of compound (13a) in CD3OD. 
 
 
Figure 3-S20. HMBC spectrum of compound (13a) in CD3OD. 
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Figure 3-S21. UV spectrum of 13a-acetate (13b). 
 
 
Figure 3-S22. IR spectrum of 13a-acetate (13b). 
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Figure 3-S23. MS spectrum of 13a-acetate (13b). 
 
 
Figure 3-S24. 
1
H NMR spectrum of 13a-acetate (13b). 
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Figure 3-S25. EIMS spectrum of verrucosidin (14). 
 
 
Figure 3-S26. 
1
H NMR spectrum of verrucosidin (14) in CDCl3. 
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Figure 3-S27. 
13
C NMR and DEPT spectra of verrucosidin (14) in CDCl3. 
 
 
Figure 3-S28. 
1
H-
1
H COSY spectrum of verrucosidin (14) in CDCl3. 
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Figure 3-S29. HMQC spectrum of verrucosidin (14) in CDCl3. 
 
 
Figure 3-S30. HMBC spectrum of verrucosidin (14) in CDCl3. 
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Figure 3-S31. EIMS spectrum of fructigenine A (15).  
 
Figure 3-S32. 
1
H NMR spectrum of fructigenine A (15) in CDCl3. 
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Figure 3-S33. 
13
C NMR and DEPT spectra of fructigenine A (15) in CDCl3. 
 
 
Figure 3-S34. 
1
H-
1
H COSY spectrum of fructigenine A (15) in CDCl3. 
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Figure 3-S35. HMQC spectrum of fructigenine A (15) in CDCl3. 
 
 
Figure 3-S36. HMBC spectrum of fructigenine A (15) in CDCl3.  
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Figure 3-S37. EIMS spectrum of verrucofortine (16). 
 
 
Figure 3-S38. 
1
H NMR spectrum of verrucofortine (16) in DMSO-d6. 
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Figure 3-S39. 
1
H NMR spectrum of verrucofortine (16) in CDCl3. 
 
 
Figure 3-S40. EIMS spectrum of cyclopenol (17). 
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Figure 3-S41. 
1
H NMR spectrum of cyclopenol (17) in CD3OD. 
 
 
 
Figure 3-S42. 
1
H NMR spectrum of cyclopenol (17) in acetone-d6. 
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Figure 3-S43. 
13
C NMR and DEPT spectra of cyclopenol (17) in CD3OD.  
 
 
Figure 3-S44. 
1
H-
1
H COSY spectrum of cyclopenol (17) in CD3OD. 
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Figure 3-S45. HMQC spectrum of cyclopenol (17) in CD3OD. 
 
 
Figure 3-S46. HMBC spectrum of cyclopenol (17) in CD3OD. 
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Figure 3-S47. EIMS spectrum of cyclopenin (18). 
 
 
Figure 3-S48. 
1
H NMR spectrum of cyclopenin (18) in CD3OD. 
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Figure 3-S49. 
1
H NMR spectrum of cyclopenin (18) in CDCl3. 
 
 
Figure 3-S50. 
13
C NMR and DEPT spectra of cyclopenin (18) in CD3OD. 
 
116 
 
Figure 3-S51. 
1
H-
1
H COSY spectrum of cyclopenin (18) in CD3OD. 
 
 
Figure 3-S52. HMQC spectrum of cyclopenin (18) in CD3OD. 
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Figure 3-S53. HMBC spectrum of cyclopenin (18) in CD3OD. 
 
 
Figure 3-S54. EIMS spectrum of penipratynolene (19). 
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Figure 3-S55. 
1
H NMR spectrum of penipratynolene (19) in DMSO-d6. 
 
 
 
Figure 3-S56. 
1
H NMR spectrum of penipratynolene (19) in acetone-d6. 
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Figure 3-S57. 
13
C NMR and DEPT spectra of penipratynolene (19) in DMSO-d6. 
 
 
 
Figure 3-S58. 
1
H-
1
H COSY spectrum of penipratynolene (19) in DMSO-d6. 
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Figure 3-S59. HMQC spectrum of penipratynolene (19) in DMSO-d6. 
 
 
Figure 3-S60. HMBC spectrum of penipratynolene (19) in DMSO-d6. 
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Figure 3-S61. EIMS spectrum of cyclo-(L-Trp-L-Phe) (20). 
 
 
 
Figure 3-S62. 
1
H NMR spectrum of cyclo-(L-Trp-L-Phe) (20) in DMSO-d6. 
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Figure 3-S63. 
13
C NMR and DEPT spectra of cyclo-(L-Trp-L-Phe) (20) in DMSO-d6. 
 
 
Figure 3-S64. 
1
H-
1
H COSY spectrum of cyclo-(L-Trp-L-Phe) (20) in DMSO-d6. 
 
123 
 
Figure 3-S65. HMQC spectrum of cyclo-(L-Trp-L-Phe) (20) in DMSO-d6. 
 
 
Figure 3-S66. HMBC spectrum of cyclo-(L-Trp-L-Phe) (20) in DMSO-d6. 
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Figure 3-S67. EIMS spectrum of aspterric acid (21). 
 
 
Figure 3-S68. 
1
H NMR spectrum of aspterric acid (21) in CD3OD. 
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Figure 3-S69. 
1
H NMR spectrum of aspterric acid (21) in CDCl3. 
 
 
 
Figure 3-S70. 
13
C NMR and DEPT spectra of aspterric acid (21) in CD3OD. 
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Figure 3-S71. 
1
H-
1
H COSY spectrum of aspterric acid (21) in CD3OD. 
 
 
Figure 3-S72. HMQC spectrum of aspterric acid (21) in CD3OD. 
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Figure 3-S73. HMBC spectrum of aspterric acid (21) in CD3OD. 
 
 
 
 
Figure 3-S74. EIMS spectrum of viridicatol (22) in DMSO-d6. 
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Figure 3-S75. 
1
H NMR spectrum of viridicatol (22) in DMSO-d6. 
 
 
 
Figure 3-S76. 
13
C NMR spectrum of viridicatol (22) in DMSO-d6. 
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Figure 3-S77. 
1
H-
1
H COSY spectrum of viridicatol (22) in DMSO-d6. 
 
 
Figure 3-S78. HMQC spectrum of viridicatol (22) in DMSO-d6. 
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Figure 3-S79. HMBC spectrum of viridicatol (22) in DMSO-d6. 
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4. Isolation and Characterization of Antifungal Compounds from a 
Marine-Derived Penicillium copticola TPU1270 
4.1 Introduction  
Microorganisms have made a phenomenal contribution to the health of people (Sanchez, S., 
2009). Marine-derived fungi have proven to be a rich source for the discovery of new natural 
products (Bhatnagar, I., 2010). During our continuous work for new compounds discovery, a 
strain of Penicillium copticola TPU1270, isolated from a marine bubble sample collected at 
Iriomote Island, Okinawa Prefecture, Japan showed antifungal activity against Mucor hiemalis 
(inhibiton zone of 20 mm at 200 μg/disc). Bioassay-guided isolation from the culture broth of 
strain TPU1270 yielded a new natural open-chain hemisuccinimide, named penicillimide (23), 
together with five known eremophilane sesquiterpenes: sporogen-AO 1 (24) (Tirilly Y.,1983) 
(Tanaka S.,1984), 3-acetyl-13-deoxyphomenone (25) (Schneider G., 1997) (Huang Y. F., 2008), 
6-dehydropetasol (26) (Sugawara, F., 1993), 7-hydroxypetasol (27) (Sugawara, F., 1993), and 
petasol (28) (Sugama K., 1983). The isolation and antifungal activities of compounds 23–28 are 
described. 
 
Figure 4-1. Structures of compounds 23–28 isolated from Penicillium copticola TPU1270. 
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4.2 Results and Discussion  
A new natural open-chain hemisuccinimide, named penicillimide (23) and five known 
compounds 24–28. Penicillimide (23) was first isolated from a culture broth of fungus were 
obtained from the culture broth of strain TPU1270. 
The structures of known compounds 24–28 were identified by comparing their 
spectroscopic data with the reported values for sporogen-AO 1 (24) (Tirilly Y.,1983) (Tanaka 
S.,1984), 3-acetyl-13-deoxyphomenone (25) (Schneider G., 1997) (Huang Y. F., 2008), 
6-dehydropetasol (26) (Sugawara, F., 1993), 7-hydroxypetasol (27) (Sugawara, F., 1993), and 
petasol (28) (Sugama K., 1983) (Le D. H.,2013) (Yurchenko, A. N., 2013). 
 
4.2.1 Screening Bioassay 
Antifungal screening was carried out using Mucor hiemalis IAM 6088 by the paper disc 
method.
 
The test microorganism was inoculated to a petri dish containing the PDA (Potato 
dextrose agar). A sterile antibiotic filter disc (diameter, 6 mm, Advantec, Tokyo, Japan) with 
the sample was placed in the dish and cultured for 2 days at 25°C. The inhibition zone in 
diameter (mm) was measured.  
The crude extract of the fungual strain TPU1270 showed the inhibitory activity against M. 
genevensis (inhibition zone: 20 mm at 200 μg/disc) among 10 crude extracts of marine–derived 
fungi, while other strains showed no activity.  
 
4.2.2 Isolation of Compounds 
The whole broth after a 21-d static culture was added a half volume of acetone and filtered. 
After the evaporation of acetone, the filtrate was separated with an ODS column followed by 
repeated HPLC (ODS) to afford compounds 23–28. (Figure 4-2) 
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Penicillium copticola (strain TPU1270) 
    seed culture (30 mL, 27℃, 150 r.p.m, 3 days)  
    main culture (3.0 L, RT, static, 21 days) 
broth 
     added acetone and filtered 
filtrate 
     evaporate acetone 
     absorbed on an ODS column  
MeOH (%)               eluted with a stepwise gradient of H2O/MeOH 
     
 Fr.3 (30 %)         Fr.4 (40 %)         Fr.5 (50 %)       Fr.6 (60%)      Fr.7 (70%) 
          (174.6 mg)         (309.2 mg)         (217.9 mg)        (181.2 mg )     (30.4 mg) 
                                                              
                                                             
 
 
Figure 4-2. Isolation procedure for the whole broth extract. 
 
4.2.3 Structure Determination of New Natural Compound 
Penicillimide (23) was obtained as a pale yellow solid with the molecular formula 
C13H14NO5Cl determined by HRESIMS (m/z 299.0555 [M]
+
). The 
1
H and 
13
C NMR spectra 
revealed 12 proton and 13 carbon signals (Table 4-1). The 
1
H and 
13
C NMR signals were 
assigned by the analysis of 
1
H-
1
H COSY, HMQC and HMBC correlations (Table 4-1). In the 
13
C NMR spectrum of 23, one oxygenated methyl, three sp
3 
methylene, three sp
2
 methine, two 
sp
2
 quaternary, one oxygenated sp
2 
quaternary and three carbonyl carbons were assigned by the 
analysis of 1D and 2D NMR spectra. 
1
H-
1
H COSY correlations were observed between H-3 (δ 
2.61) / H-4 (δ 2.84) and H-13 (δ 6.86) / H-14 (δ 7.03) and gave the partial structures I and II. 
These partial structures were connected by the HMBC correlations (Figure 4-3). 
The differences in the molecular formula and weight between compound 23 and 
coniothyriomycin were two protons and 2 Da. NMR data due to the 
2-(3-chloro-4-hydroxyphenyl)acetylamide moiety in 23 were very similar to those of the same 
 
24 (15.0 mg) 25 (4.0 mg)     
HPLC-LH20  
33 % MeOH                                           
27 (5.5 mg) 
crystallized                                          
HPLC-ODS  
55 % MeOH                                          
HPLC-ODS  
75% MeOH                                          
HPLC-ODS  
66 % MeOH                                          
 23 (30.0 mg) 
26 (15.1 mg)     28 (12.0 mg) 
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moiety in coniothyriomycin, which was previously identified as an antifungal metabolite from 
the fungus Coniothryrium sp. (Krohn, K., 1992). A difference in the structures of compound 23 
and coniothyriomycin was detected at the dicarboxylic acid units. Compound 23 had the 
succinic acid unit while coniothyriomycin had the fumaric acid unit (2’-succnic acid unit). 
Thus, the structure of compound 23 was assigned as shown in Figure 4-3 and named 
penicillimide (Note 4-1).      
 
Table 4-1. 
13
C (100 MHz) and 
1
H (400 MHz) NMR data for compound 23 (acetone-d6 and 
CD3OD). 
  Measured in acetone-d6   Measured in CD3OD      
C# δC    δH, mult. (J in Hz)   δC    δH, mult. (J in Hz)  HMBC 
1 128.3    
 
127.9 
   
2 132.1 
 
7.31, d (2.2) 
 
132.1 
 
7.22, d (2.1) 3, 4, 6, 7 
3 121.1 
   
121.7 
   
4 153.1 
   
153.6 
   
   4-OH   ---   8.67, brs   ---       
5 117.7 
 
6.95, d (8.3) 
 
117.8 
 
6.86, d (8.3) 1, 3, 4 
6 130.4 
 
7.10, dd (2.2, 8.3) 
 
130.3 
 
7.03, dd (2.1, 8.3) 2, 4, 7 
7 43.1 
 
3.81, s 
 
43.3 
 
3.67, s 1, 2, 6, 8 
8 172.4 
   
173.8 
   
   8-NH --- 
 
9.78, brs 
 
--- 
   
1’ 173.7 
   
174.9 
   
2’ 33.1 
 
2.94, dd (6.5, 6.5) 
 
33.1 
 
2.84, dd (5.7, 7.2) 1’, 3’, 4’ 
3’ 28.8 
 
2.59, dd (6.5, 6.5) 
 
29.1 
 
2.61, dd (5.7, 7.2) 1’, 2’, 4’ 
4’ 174.1 
   
175.2 
   
5’ 52.0  
 
3.61, s 
 
52.4 
 
3.66, s 4’ 
 
 
 
Figure 4-3. 
1
H-
1
H COSY and HMBC correlations for compound 23 
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4.2.4 Structure Determination of Known Compounds 
Compound 24 was obtained as a colorless oil. The molecular weight and formula (248 and 
C15H20O3) of 24 was determined by 
1
H and 
13
C NMR and EIMS data. The structure of 
compound 24 was determined by the HMBC, HMQC and 
1
H-
1
H COSY correlations and 
compound 24 was confirmed as sporogen-AO 1. 
Compound 25 was obtained as a pale yellow oil. The molecular weight and formula (290 
and C17H22O4) of 25 was determined by 
1
H and 
13
C NMR and EIMS data. The additional acetyl 
group was confirmed by 
13
C NMR spectrum and molecular formula. Thus, compound 25 was 
confirmed as 3-acetyl-13-deoxyphomenone. 
Compound 26 was obtained as a colorless oil. The molecular weight and formula (232 and 
C15H20O2) of 26 was decided by 
1
H and 
13
C NMR and EIMS data. One singlet signal at δ 6.86 
of H-6 in
 1
H NMR, together with the comparison with the 
1
H NMR of petasol, compound 26 
was determined as 6-dehydropetasol. 
Compound 27 was obtained as a colorless oil. The molecular weight and formula (250 and 
C15H22O3) of 27 was determined by 
1
H and 
13
C NMR and EIMS data. The 
1
H NMR spectrum 
showed similar signals as that of sporogen-AO 1. The difference in the 
1
H NMR spectra 
between 26 and 27 was that two doublets at δ 2.32 and 1.75 were observed in the 1H NMR 
spectrum of compound 27, and one singlet at δ 3.31 in the spectrum of 26. Thus, compound 27 
was identified as 7-hydroxypetasol. 
Compound 28 was obtained as a colorless oil. The molecular weight and formula (234 and 
C15H22O2) of 28 was determined by 
1
H and 
13
C NMR and EIMS spectra.  The lower-field 
region of 
1
H NMR spectrum was similar to that of 7-hydroxypetasol while the higher-field 
region showed some differences. The comparison of the molecular formula of 28 and 27 
revealed the difference one oxygen atom. Based on these information, compound 28 was 
identified as Petasol. 
4.2.5 Biological Activity  
The antifungal activity against M. hiemalis, A. fumigates and the anti-mycobacterial   
activity against Mycobacterium smegmatis NBRC 3207 of compounds 23—28 were evaluated 
by the paper disc method (Ericsson, H., 1960) and the results of antifungal activity were shown 
in Table 4-2.  
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Table 4-2. Antifungal activity (inhibition zone, mm) against Mucor hiemalis and 
Aspergillus fumigatus. 
Compound 
M. hiemalis  A. fumigatus 
40 μg/disc 80 μg/disc  40 μg/disc 80 μg/disc 
23 
24 
25 
26 
27 
28 
—
a
 
7 
— 
11 
— 
8 
— 
9 
9 
15 
— 
10 
 
— 
7 
— 
9 
— 
11 
— 
10 
9 
16 
— 
13 
Amphotericin B (10 μg/disc) 12  13 
  a
An inhibition zone was not detected. 
 
    Compounds 24, 25, 26 and 28 showed antifungal activity against both Mucor hiemalis and 
Aspergillus fumigates, but no activity against Mycobacterium smegmatis NBRC 3207 of 
compounds 23—28 was observed.  
Butenoate derivatives such as coniothyriomycin (Krohn, K. 1992, 2003) and 
3-phenylcarbamoyl-arylic acid methyl ester (Bobkova, T.S. 1977), were reported to possess the 
remarkable antifungal and herbicidal activities. Compound 23, the derivative of 
coniothyriomycin, was detected successfully from two days` culture broth by EIMS 
measurement, while coniothyriomycin was not found. Thus, compound 23 was considered as 
originally produced by the fungus strain, TPU1270. Unfortunately, the results showed 
compound 23 had no antifungal activity against M. hiemalis and A. fumigatus at 80 μg/disc. 
Therefore, the fumaric acid partial structure will be essential for the antifungal activity of 
butenoate derivatives. 
Compounds 24, 26 and 28 showed the inhibition zone against M. hiemalis and A. 
fumigatus at 40 μg/disc. Compound 25 was active against M. hiemalis and A. fumigatus at 80 
μg/disc and compound 27 showed no activity. Related sesquiterpenoids were isolated from 
various fungi, such as Penicillium citrinum (Yurchenko, A.N. 2013), Petasies fragrans (Sugama, 
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K. 1983), Penicillium sp. SS080624SCf1 (Motohashi, K., 2009), Drechslera gigantea (Bunkers, 
G., 1990), Penicillium sp. BL27-2 (Huang, Y. F., 2008), Hansfordia sp. (Schneider, G., 1997), 
Aspergillus oryzae (Tanaka, S., 1984), Sarcographa tricosa (Le, D. H., 2013) and 
Apiognomonia sp. f24023 (Kawahara, T., 2013). The cytotoxic, antimicrobial and phytotoxic 
activites were described in these reports. The results for similiar antifungal activity in this study 
suggested that the hydroxyl group attached to C-7 will lead to the loss of the antifungal activity 
of these sesquiterpenoids. 
 
4.3 Experimental Section 
4.3.1 General Experimental Procedures 
NMR spectral data were obtained by a JEOL JNM-AL-400 NMR spectrometer (JEOL 
Ltd., Japan; 400 MHz for 
1
H and 100 MHz for 
13
C) in CDCl3 (δH 7.24, δC 77.23) or CD3OD (δH 
3.31, δC 49.15). Mass spectra were recorded with a JEOL JMS-MS 700 mass spectrometer (EI 
or FAB mode with m-nitrobenzyl alcohol or glycerol as the matrix). UV spectra were obtained 
on a Hitachi U-3310 UV-Visible spectrophotometer (Hitachi, Ltd., Japan) and IR spectra on a 
PerkinElmer Spectrum One Fourier transform infrared spectrometer (Waltham, MA, USA). 
Optical rotations were measured with a JASCO P-2300 digital polarimeter (JASCO, Ltd., 
Japan). Preparative HPLC was conducted using a Toyosoda CCPU instrument equipped with a 
Tosoh UV-8010 detector. 
4.3.2 Isolation, Identification, and Fermentation of Producing Bacterium 
The fungus strain TPU1270 was isolated from a marine bubble sample at the beach of 
Iriomote Island in Okinawa, Japan in July, 2012. Approximately 1 mL of the seawater was 
macerated in 25 mL sterilized seawater with 1.0 % SDS and 50 μL of the suspension was plated 
to a agar plate (glycerol 0.6%, arginine 0.1%, K2HPO4 0.1%, MgSO4 0.05%, agar 1.5% and the 
antibiotics (cycloheximide 100 μg/mL, rifampin 5 μg/mL) in natural seawater). The fungus 
strain TPU1270 was identified as Penicillium copticola by a comparison of 228 bp ITS1 rDNA 
sequences (100% match).   
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Figure 4-4. Pure cultures of Penicillium copticola TPU1270 in dish 
The culture of strain TPU1270 was matintained on a PDA (Difco Laboratories, Detroit, MI, 
USA) plate. The mycelia grown on the agar plate was inoculated in a 100-mL Erlenmeyer flask 
containing 50 mL of PD broth as the seed medium. The flasks were shaken on a shaker (150 
r.p.m) at 27 ℃ for 3 days. Aliquots (2 mL) of the seed culture were inoculated to 500-mL 
Erlenmeyer flasks containing each 200 mL of the main medium (3% sucrose, 3% soluble starch, 
1% malt extract, 0.3% Ebios (Asahi Food & Healthcare Co. Ltd., Tokyo, Japan), 0.5% KH2PO4 
and 0.05% MgSO4·7H2O; adjusted to pH 6.0 before sterilization). The production culture was 
carried out at room temperature for 21 days. 
 
4.3.3 Bioassay 
Compounds 23−28 were tested for antimicrobial activity against Mycobacterium 
smegmatis NBRC 3207 (48 hours at 37℃), Asperillus fumigatus IAM 13869 (48 hours at 25℃) 
and Mucor hiemalis IAM 6088 (48 hours at 25℃). A sterile antibiotic filter disk (6 mm in 
diameter), treated with the test sample was placed in the dish. After incubation, the inhibition 
zone in diameter (mm) was measured. 
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4.3.4 Extraction and Isolation of Compounds 
The whole broth (3 L) was added the same volume of acetone and filtered. After 
evaporation under reduced pressure to remove acetone, the aqueous solution was subjected to 
ODS column chromatography by the stepwise gradient elution with H2O-MeOH mixtures 
(100:0 to 0:100, v/v) to afford 10 fractions. About 30 mg of penicillimide (23) was obtained as 
a crystal from 40% MeOH fraction. Sporogen-AO 1 (24, 15.0 mg) was obtained by separation 
of the 50% MeOH fraction with preparative reversed-phase HPLC (Senshu Scientific co., Ltd., 
Pegasil ODS SP100 column, 250 × 10 mm, 5 μm; MeOH-H2O=55:45; 2.0 ml/min; UV 210 
nm). 3-Acetyl-13-deoxyphomenone (25, 4.0 mg) was isolated from the 70% MeOH fraction by 
preparative HPLC (ODS, MeOH-H2O = 75:25), and 6-dehydropetasol (26, 15.1 mg) and 
petasol (28, 12.0 mg) were obtained from the 60% MeOH fraction by preparative ODS HPLC 
(MeOH-H2O = 66:34). Preparative HPLC (ODS, MeOH-H2O=33:64) of the 30% MeOH 
fraction yielded 7-hydroxypetasol (27, 5.5 mg).  
 
 
Figure 4-5. Chromatography for the analysis of penicillimide (23) with HPLC systems (ODS 
Senshu Scientific co., Ltd., Pegasil ODS SP100 column, 250 × 10 mm, 5 μm; 
MeOH-H2O=44:56; 2.0 ml/min; UV 210 nm) 
 
 
penicillimide 
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Penicillimide (23): pale yellow crystals. UV (MeOH) λmax nm (log ε) 202 (3.69), 280 (2.80). IR 
(KBr) νmax 3419, 1739, 1734, 1635, 1501, 1424, 1364, 1287, 1059, 1048 cm
-1
. HREIMS (m/z) 
299.0555 ([M]
+
; calcd for C13H14NO5Cl, 299.0561). 
1
H and 
13
C NMR (acetone-d6 and CD3OD), 
see Table 4-1. 
 
Sporogen-AO 1 (24): obtained as a colorless oil; EIMS (m/z): 248; Molecular formula: 
C15H20O3; [α]
23
D
 
+14 (c 0.1, MeOH); 
1
H NMR data in CDCl3: δ 1.20 (3H, s), 1.24 (3H, d, 6.8 
Hz), 1.42 (1H, m), 1.79 (1H, m), 1.85 (3H, brs), 2.13 (1H, m), 2.32 (1H, ddd, 14.2 Hz, 3.2 Hz, 
2.6 Hz), 2.63 (1H, tdd, 14.1 Hz, 4.6 Hz, 1.8 Hz), 3.31 (1H, s), 3.60 (1H, td, 10.8 Hz, 4.5 Hz), 
5.08 (1H, m), 5.09 (1H, brs), 5.74 (1H, d, 2.0 Hz). 
 
3-Acetyl-13-deoxyphomenone (25): obtained as a pale yellow oil; EIMS (m/z): 290; Molecular 
formula: C17H22O4; [α]
22
D
 
+126 (c 0.1, MeOH)
1
H NMR data in CDCl3: δ 1.10 (3H, d, 6.8 Hz), 
1.24 (3H, s), 1.43 (1H, m), 1.71 (1H, t, 8.7 Hz), 1.85 (3H, s), 2.04 (1H, m), 2.15 (1H, m), 2.33 
(1H, ddd, 14.8 Hz, 4.2 Hz, 2.7 Hz), 2.54 (1H, dddd, 15.1 Hz, 13.9 Hz, 4.6 Hz, 2.2 Hz), 3.30 (1H, 
s), 4.84 (1H, ddd, 10.7 Hz, 9.4 Hz, 4.8 Hz), 5. 09 (1H, s), 5.75 (1H, d, 1.9 Hz).  
 
6-Dehydropetasol (26): obtained as a colorless oil; EIMS (m/z): 232; Molecular formula: 
C15H20O2; [α]
22
D
 
+70 (c 0.1, MeOH); [α]22D
 
+300 (c 0.1, MeOH); 
1
H NMR data in CDCl3: δ 
1.13 (3H, s), 1.21 (3H, d, 6.7 Hz), 1.36 (1H, m), 1.41 (1H, m), 1.80 (1H, brs), 1.95 (3H, s), 2.22 
(1H, m), 2.35 (1H, ddd, 14.3 Hz, 4.2 Hz, 2.3 Hz), 2.49 (1H, dddd, 14.1 Hz, 13.9 Hz, 5.6 Hz, 1.1 
Hz), 3.64 (1H, m), 5.06 (1H, brs), 5.16 (1H, brs), 6.05 (1H, d, 1.0 Hz), 6.86 (1H, s). Exact 
Mass: 232.1463 
 
7-hydroxypetasol (27): obtained as a colorless oil; EIMS (m/z): 250; Molecular formula: 
C15H22O3; [α]
23
D
 -47 (c 0.1, MeOH); 1H NMR data in CDCl3: δ 1.11 (3H, d, 6.7 Hz), 1.14 (3H, 
s), 1.38 (1H, m), 1.64 (1H, m), 1.75 (1H, d, 14.8 Hz), 1.77 (3H, s), 2.18 (1H, m), 2.31 (1H, m), 
2.32 (1H, d, 14.8 Hz), 2.53 (1H, ddd, 13.9 Hz, 9.6 Hz, 4.3 Hz), 3.61 (1H, ddd, 10.5 Hz, 10.3 Hz, 
5.4 Hz), 4.83 (1H, s), 4.94 (1H, s), 5.92(1H, brs).  
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Petasol (28):
 
obtained as a colorless oil; EIMS (m/z): 234; Molecular formula: C15H22O2; [α]
23
D
 
+124 (c 0.1, MeOH); 
1
H NMR data in CDCl3: δ 1.04 (3H, 6.7 Hz), 1.14 (3H, s), 1.30 (1H, m), 
1.41 (1H, m), 1.70 (3H, brs), 1.84 (1H, t, 13.6 Hz), 1.99 (1H, dd, 12.9 Hz, 4.5 Hz), 2.13 (1H, m), 
2.31 (1H, ddd, 14.9 Hz, 4.8 Hz, 2.6 Hz), 2.41 (1H, tdd, 14.9 Hz, 5.0 Hz, 2.0 Hz), 3.07 (1H, dd, 
14.2 Hz, 4.6 Hz), 3.59 (1H, td, 10.6 Hz, 4.3 Hz), 4.79 (1H, s), 4.95 (1H, s), 5.74 (1H, d, 1.4 
Hz). 
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4.4 Supporting Spectral Data for Compounds 23—28 
 
Figure 4-S1. UV spectrum of penicillimide (23). 
 
 
 
Figure 4-S2. IR spectrum of penicillimide (23) (KBr). 
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Figure 4-S3. EIMS spectrum of penicillimide (23). 
 
 
Figure 4-S4. 
1
H NMR spectrum of penicillimide (23) in CD3OD. 
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Figure 4-S5. 
1
H NMR spectrum of penicillimide (23) in acetone-d6. 
 
 
 
Figure 4-S6. 
13
C NMR spectrum of penicillimide (23) in CD3OD. 
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Figure 4-S7. 
13
C NMR spectrum of penicillimide (23) in acetone-d6. 
 
 
 
Figure 4-S8. 
1
H-
1
H COSY spectrum of penicillimide (23) in CD3OD. 
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Figure 4-S9. HMQC spectrum of penicillimide (23) in CD3OD. 
 
 
Figure 4-S10. HMBC spectrum of penicillimide (23) in CD3OD. 
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Figure 4-S11. EIMS spectrum of sporogen-AO 1 (24). 
 
 
 
Figure 4-S12. 
1
H NMR spectrum of sporogen-AO 1 (24) in CD3OD. 
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Figure 4-S13. 
1
H NMR spectrum of sporogen-AO 1 (24) in CDCl3. 
 
 
 
Figure 4-S14. 
13
C NMR spectrum of sporogen-AO 1 (24) in CD3OD. 
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Figure 4-S15. 
1
H-
1
H COSY spectrum of sporogen-AO 1 (24) in CD3OD. 
 
 
Figure 4-S16. HMQC spectrum of sporogen-AO 1 (24) in CD3OD. 
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Figure 4-S17. HMBC spectrum of sporogen-AO 1 (24) in CD3OD. 
 
 
 
 
 
Figure 4-S18. UV spectrum of 3-acetyl-13-deoxyphomenone (25). 
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Figure 4-S19. IR spectrum of 3-acetyl-13-deoxyphomenone (25). 
 
 
Figure 4-S20. EIMS spectrum of 3-acetyl-13-deoxyphomenone (25). 
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Figure 4-S21. 
1
H NMR spectrum of 3-acetyl-13-deoxyphomenone (25) in CD3OD. 
 
 
Figure 4-S22. 
1
H NMR spectrum of 3-acetyl-13-deoxyphomenone (25) in CDCl3. 
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Figure 4-S23. 
13
C NMR spectrum of 3-acetyl-13-deoxyphomenone (25) in CD3OD. 
 
 
 
Figure 4-S24. 
1
H-
1
H COSY spectrum of 3-acetyl-13-deoxyphomenone (25) in CD3OD. 
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Figure 4-S25. HMQC spectrum of 3-acetyl-13-deoxyphomenone (25) in CD3OD. 
 
 
Figure 4-S26. HMBC spectrum of 3-acetyl-13-deoxyphomenone (25) in CD3OD. 
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Figure 4-S27. EIMS spectrum of 6-dehydropetasol (26). 
 
 
Figure 4-S28. 
1
H NMR spectrum of 6-dehydropetasol (26) in CDCl3. 
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Figure 4-S29. 
13
C NMR spectrum of 6-dehydropetasol (26) in CDCl3. 
 
 
Figure 4-S30. 
1
H-
1
H COSY spectrum of 6-dehydropetasol (26) in CDCl3. 
 
157 
 
Figure 4-S31. HMQC spectrum of 6-dehydropetasol (26) in CDCl3. 
 
 
Figure 4-S32. HMBC spectrum of 6-dehydropetasol (26) in CDCl3. 
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Figure 4-S33. Positive FABMS spectrum of 7-hydroxypetasol (27). 
 
 
Figure 4-S34. Negative FABMS spectrum of 7-hydroxypetasol (27). 
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Figure 4-S35. 
1
H NMR spectrum of 7-hydroxypetasol (27) in CD3OD. 
 
 
 
Figure 4-S36. 
1
H NMR spectrum of 7-hydroxypetasol (27) in CDCl3. 
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Figure 4-S37. 
13
C NMR spectrum of 7-hydroxypetasol (27) in CD3OD. 
 
 
 
 
Figure 4-S38. EIMS spectrum of petasol (28). 
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Figure 4-S39. 
1
H NMR spectrum of petasol (28) in CDCl3. 
 
 
 
Figure 4-S40. 
13
C NMR spectrum of petasol (28) in CDCl3. 
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Figure 4-S41. 
1
H-
1
H COSY spectrum of petasol (28) in CDCl3. 
 
Figure 4-S42. HMQC spectrum of petasol (28) in CDCl3. 
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Figure 4-S43. HMBC spectrum of petasol (28) in CDCl3. 
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